Æâ²Ê³ØÂèÆó¹ÖºÂ
¡Ô¸¦µæ³µÍסÕ
½Û´Ä´ï
¡¡½Û´Ä´ï³Ø¤Ç¤Ï¡¢¿´ÉÔÁ´¤ÎÉÂÂÖ²òÌÀ¤Ë¤Ä¤¤¤Æ¤Î´ðÁø¦µæ¤È¤È¤â¤Ë¡¢µõ·ìÀ¿´¼À´µ¤äÉÔÀ°Ì®¤Î´µ¼Ôͽ¸å¤ËľÀÜ´Ô¸µ¤Ç¤¤ëÎ×¾²¸¦µæ¤ò¼çÂΤȤ·¤Æ¤¤¿¡£
1. ¶É½ê¿´µ¡Ç½¤ÎÄêÎÌŪɾ²ÁË¡¤Ë´Ø¤¹¤ëÎ×¾²Åª¡¢¼Â¸³Åª¸¡Æ¤
¡¡¿´Â¡Ä¶²»ÇÈË¡¤Î¿ÊÊâ¤Ë¤È¤â¤Ê¤¤¡¢È󿯽±Åª¶É½ê¿´µ¡Ç½É¾²Á¤¬²Äǽ¤È¤Ê¤Ã¤Æ¤¤¿¡£ÆÃ¤Ë¡¢ÁÈ¿¥¥É¥×¥éË¡¤òÍѤ¤¤ì¤ÐÄêÎÌŪ¤Ê¶É½ê¿´µ¡Ç½É¾²Á¤¬²Äǽ¤È¤Ê¤Ã¤Æ¤¤Æ¤¤¤ë¡£¤½¤³¤Ç¡¢¿´Ë¼ºÙư¤ª¤è¤Óµõ·ìÀ¿´¼À´µ¤òÂоݤˡ¢ÁÈ¿¥¥É¥×¥éË¡¤Ë¤è¤ë¿´µ¡Ç½É¾²Á¤ÎÍÍÑÀ¤Ë¤Ä¤¤¤Æ¸¡Æ¤¤·Êó¹ð¤·¤Æ¤¤¿¡£¤Þ¤¿¡¢Æ°Êª¼Â¸³¤Ë¤ª¤¤¤Æ½¾Íè¤è¤ê»°¼¡¸µ¥¹¥È¥ì¥¤¥ó²òÀϤòÍѤ¤¤¿¶É½ê¿´µ¡Ç½¤Îɾ²Á¤ò¸¡Æ¤¤·¤Æ¤¤Æ¤¤¤ë¡£¤³¤Î´ðÁÃŪ¸¡Æ¤¤ò¤â¤È¤Ë¡¢ÁÈ¿¥¥É¥×¥éË¡¤òÍѤ¤¤¿¿´µ¡Ç½É¾²Á¤ÎÂÅÅöÀ¤òưʪ¼Â¸³¤Ë¤ª¤¤¤Æ¤â¸¡Æ¤Ãæ¤Ç¤¢¤ë¡£ÁÈ¿¥¥É¥×¥éË¡¤ò±þÍѤ·¤Æ¡¢¿´Â¡Ä¶²»Çȸ¡ºº¤Ç¤â¥¹¥È¥ì¥¤¥ó²òÀϤ¬Î×¾²Åª¤Ë²Äǽ¤È¤Ê¤Ã¤Æ¤¤Æ¤ª¤ê¡¢¤³¤ì¤Ë´Ø¤¹¤ëÎ×¾²Åª¡¢¼Â¸³Åª¸¡Æ¤¤ò·Ñ³¤¹¤ëͽÄê¤Ç¤¢¤ë¡£
£². ¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¡¦±¿Æ°ÎÅË¡¤Ë´Ø¤¹¤ë¸¦µæ
¡¡¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¤Ï¡¢EBM¤Ë¤â¤È¤Å¤¯¿´¶Ú¹¼ºÉ¸å¤ÎºÆ¹¼ºÉ¡¢¿´ÉÔÁ´¤ÎͽËɰ峨¤È¤·¤Æ³ÎΩ¤µ¤ì¤Æ¤¤¿¡£º£¸å¡¢±¿Æ°¤Î¤ß¤Ê¤é¤º¡¢±ÉÍÜ¡¢¹Ôư²ðÆþ¤Ê¤É¥«¥¦¥ó¥»¥ê¥ó¥°¤ò´Þ¤à¿Í×ÁÇ¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¤È¤·¤ÆÁí¹çŪ¤Ë»Ü¹Ô¤¹¤ë¤¿¤á¿·¤¿¤Ë·ò¹¯²Ê³Ø¥»¥ó¥¿¡¼¤òÀߤ±Æþ±¡¡¢³°Íè´µ¼Ô¤Ë»Ü¹Ô¤·¤Æ¤¤¤ë¡£Æ±»þ¤ËËýÀ¿´ÉÔÁ´¤Ë¤ª¤±¤ë¿´µ¡Ç½¤Î²þÁ±¡¢¿´ÉÔÁ´¾õÂ֤ΤΥµ¥¤¥È¥«¥¤¥ó¡¢¼«Î§¿À·Ðµ¡Ç½¤ÎÊѲ½¤Ê¤É¤ò¸¡Æ¤¤·¡¢¤½¤ÎÍÍÑÀ¤òÊó¹ð¤·¤Æ¤¤¿¡£¤Þ¤¿¡¢Â¿Í×ÁÇ¥ê¥Ï¤È¤·¤Æ¤Î¹Ôư²ðÆþ¤Ï¡¢¿´¶Ú¹¼ºÉ¤Î¤ß¤Ê¤é¤º¡¢¹â·ì°µ¡¢¹â»é·ì¾É¡¢ÅüǢɤʤÉÀ¸³è½¬´·É¤ËÂФ¹¤ë¼£ÎÅË¡¤È¤·¤ÆÍ¸ú¤Ç¤¢¤ê¡¢±¿Æ°¸ú²Ì¤ÎºîÍѵ¡½ø¡¢Å¬±þÅù¤òÀ¸ÂÎÆâ¾º°µÊª¼Á¡¢ÈîËþ°äÅÁ»Ò¡¢¥¤¥ó¥¹¥ê¥ó´¶¼õÀ¡¢»é¼ÁÂå¼Õ¤ÎÌ̤è¤ê¸¦µæ¤·¤Æ¤¤¤ë¡£¤Þ¤¿¡¢·ò¹¯²Ê³Ø¥»¥ó¥¿¡¼¤Ç¤Ï¡¢Î×¾²¥¹¥Ý¡¼¥Ä°å³Ø¤È¤·¤Æ¡¢¥¹¥Ý¡¼¥Ä¿´Â¡¤ÎȯÀ¸µ¡½ø¡¢¸ÆµÛµ¡Ç½¤ÎÁí¹çŪɾ²ÁË¡¤Î³«È¯¤Ê¤É¡¢±¿Æ°À¸Íý³Ø¤ÎÎ×¾²±þÍѤòÌܻؤ·¡¢³Æ¼ï¥¹¥Ý¡¼¥ÄÁª¼ê¤Î±¿Æ°ÂÑÍÆÇ½¡¢¸ÆµÛµ¡Ç½¤òÃæ¿´¤È¤·¤¿Â¬Äê¡¢¥È¥ì¡¼¥Ë¥ó¥°¥á¥Ë¥å¡¼¤Î³«È¯¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£¤³¤ì¤é¤Î¸¦µæ¤Ï¡¢±¿Æ°ÂÑÍÆÇ½Äã²¼¤Ë¤è¤Ã¤Æ°ú¤µ¯¤³¤µ¤ì¤ë¼À´µ¤ÎÍýÏÀÅªÇØ·Ê¤È¤·¤Æ¤â¸½ºß¸¦µæÃæ¤Ç¤¢¤ë¡£
£³¡¥ËýÀ¿´ÉÔÁ´Îã¤Ë¤ª¤±¤ë¸ò´¶¿À·Ð³èư¤Ë´Ø¤¹¤ë¸¦µæ
¡¡ËýÀ¿´ÉÔÁ´¤Ë¤ª¤¤¤Æ¸ò´¶¿À·Ð³èư¤Îж¿Ê¤Ïͽ¸å¤òº¸±¦¤¹¤ë¾å¤Ç½ÅÍפʻØÉ¸¤Ç¤¢¤ë¡£¸ò´¶¿À·Ð³èư¤Î¬Äê¤Ï·ìÃænoradrenaline¡¢¿´ÇïÊÑÆ°¥¹¥Ú¥¯¥È¥é¥à¤Ê¤É¤¬°ìÈÌŪ¤Ç¤¢¤Ã¤¿¤¬¡¢²æ¡¹¤Ï¶Ú¸ò´¶¿À·Ð³èư(MSNA)¤Î¬ÄêÊýË¡¤ò²ñÆÀ¤·¡¢¸ò´¶¿À·Ð³èư¤òľÀÜŪ¤Ë¬Äꤷ¤Æ¤¤¤ë¡£ËýÀ¿´ÉÔÁ´Îã¤Ë¤ª¤±¤ë¸ò´¶¿À·Ð³èư¤Îж¿Ê¤Ë´ØÍ¿¤¹¤ë°ø»Ò¤È¤·¤Æ¤Ïarterial baroreflex¡¢cardiopulmonary baroreflex¡¢metaboreflex¡¢chemoreeflex¤Î4¤Ä¤Î°µ¼õÍÆÂÎÈ¿¼Íµ¡Ç½¤¬´ØÍ¿¤·¤Æ¤¤¤ë¤ÈÊó¹ð¤µ¤ì¤Æ¤ª¤ê¡¢ËÜ»ÜÀߤˤª¤¤¤ÆÁ´¤ÆÂ¬Äê²Äǽ¤È¤Ê¤Ã¤Æ¤¤¤ë¡£¸½ºß¡¢¤³¤ì¤é¤Î°µ¼õÍÆÂÎÈ¿¼Íµ¡Ç½¤ÈMSNA¤òÍѤ¤¤ÆËýÀ¿´ÉÔÁ´Îã¤Ë¤ª¤±¤ë¸ò´¶¿À·Ð³èưж¿Ê¤ÎÉÂÂ֤ˤĤ¤¤Æ¸¡Æ¤¤·¤Æ¤¤¤ë¡£¤µ¤é¤Ë¡¢ACEÁ˳²Ìô¡¢AngIIÙɹ³Ìô¤Ê¤É¤Î¸ò´¶¿À·Ð³èư¤ËÂФ¹¤ë±Æ¶Á¤òÈæ³Ó¸¡Æ¤Ãæ¤Ç¤¢¤ë¡£
£´¡¥³Ë°å³Ø¤òÍѤ¤¤¿´§Æ°Ì®¼À´µ¤Ë¤ª¤±¤ë¿´¶ÚÞõή¤Ë´Ø¤¹¤ë¸¦µæ
¡¡³Ë°å³Ø¤òÍѤ¤¤¿¿´¶ÚÞõή¥¤¥á¡¼¥¸¥ó¥°¤Ï·ì´É¤±Æ¤Ç¤Ïɾ²Á¤Ç¤¤Ê¤¤¿´¶ÚÈù¾®½Û´Ä¤òÈ󿯽±Åª¤Î¤Ëɾ²Á²Äǽ¤Ç¤¢¤ë¡£µÞÀ¿´¶Ú¹¼ºÉ¾É¤ËÂФ¹¤ë´§Æ°Ì®·ì¹ÔºÆ·ú½Ñ¸å¤Î¿´¶ÚÈù¾®½Û´Ä½ý³²¤ÎÄêÎÌŪɾ²ÁË¡¤ò³ÎΩ¤·¤¿¡£²Ã¤¨¤Æ¡¢¿´¶ÚÈù¾®½Û´Ä½ý³²¤ËÂФ¹¤ëverapamil¤Î͸úÀ¤ò¾ÚÌÀ¤·¤¿¡£ºÇ¶á³«È¯¤µ¤ì¤¿¿´ÅÅ¿ÞÆ±´üSPECT¤òÍѤ¤¤ë¤³¤È¤Ë¤è¤ê
¡¡(1)¿´¶Ú¹¼ºÉ¸å¤Î·ìή-¼ý½ÌЪΥ(Stunned myocardium)¤Î¸¡½Ð¡¢
¡¡(2)ºÆÞõή¸å¤Î¶É½ê¿´µ¡Ç½²óÉü¤Ë¤ª¤±¤ë»Ä¸¿´¶Ú·ìή¤Î´ØÍ¿¤òÌÀ¤é¤«¤Ë¤·¤Æ¤¤¤¯¡£
£µ. ¿´¶ÚÈù¾¯½Û´Ä¤ÎºÆÀ¸¤Èɾ²Á
¡¡Ä¶²»ÇȤ±ÆºÞ¤Î³«È¯¡¢¿´¥¨¥³¡¼ÁõÃ֤βþÎɤˤè¤ê¡¢Ä¶²»ÇȤ±ÆºÞ¤ò·ÐÀÅ̮ŪÅêÍ¿¤¹¤ë¤³¤È¤Ë¤è¤Ã¤Æ¤â¿´¶Ú¥³¥ó¥È¥é¥¹¥È¥¨¥³¡¼¤¬²Äǽ¤È¤Ã¤¿¡£·ÐÀÅÌ®¿´¶Ú¥³¥ó¥È¥é¥¹¥È¥¨¥³¡¼(MCE)»£Áü¤Î»êŬ¾ò·ï¤ÈÎ×¾²Åª°ÕµÁ¤ÏÌÀ¤é¤«¤Ë¤Ê¤Ã¤Æ¤¤¤Ê¤¤¡£µÞÀ¿´¶Ú¹¼ºÉËýÀ´ü¤ËMCE¤ò»Ü¹Ô¤·¡¢¿´¶ÚÈù¾®½Û´Ä¾ã³²¤È¿´µ¡Ç½²þÁ±¡¦º¸¼¼ºÆ¹½ÃۤδØÏ¢¤ò¸¡Æ¤Ãæ¤Ç¤¢¤ë¡£¤Þ¤¿¡¢µõ·ìÀ¿´¼À´µ¤ËÂФ¹¤ë¹ü¿ñºÙ˦°Ü¿¢¤Ë¤è¤ë¿·À¸·ì´É¤ÎÄêÎÌŪɾ²Á¤ò£ÍCE¤òÍѤ¤¤Æ¤ò¸¡Æ¤Ãæ¤Ç¤¢¤ê¡¢¤½¤Î·ë²Ì¤Î°ìÉô¤òÊó¹ð¤·¤¿¡£¤µ¤é¤Ë¡¢Ä¶²»ÇȤ±ÆºÞÅêÍ¿²¼¤Ë¶¯ÅÙ¤ÎͲ»ÇȾȼͤò¹Ô¤¦¤Èbioeffect¤Ë¤è¤êÌÓºÙ·ì´É¤¬Ç˲õ¤µ¤ì¤ë»ö¤¬ÌÀ¤é¤«¤È¤Ê¤Ã¤Æ¤¤¿¡£¤³¤Îbioeffect¤òÍøÍѤ·MCE¤Ë¤è¤ëdrug-delivery, cell- delivery¤Î´ðÁø¡Æ¤¤ò³«»Ï¤·¤Æ¤¤¤ë¡£
£¶¡¥¿´¶ÚÁÈ¿¥À¾õ¤È¿´µ¡Ç½¤ÎÈ󿯽±ÅªÉ¾²Á
¡¡¹¼ºÉ¿´¶Ú¤Ë¤ª¤±¤ë¿´¶ÚÆâËì³°Ë즤ÎÁÈ¿¥À¾õ¤ÎÊѲ½¤¬º¸¼¼·ÁÂÖ°Ý»ý¤ËµÚ¤Ü¤¹±Æ¶Á¤ÏÌÀ¤é¤«¤Ë¤µ¤ì¤Æ¤¤¤Ê¤¤¡£¿´¶ÚIntegrated backscatter (IBS)¤Ë¤è¤ê¡¢¿´¶ÚÆâË즡¦³°Ë즤Îviability¤¬¸ÄÊ̤˲òÀϲÄǽ¤È¤Ê¤Ã¤¿¡£½é²ó¿´¶Ú¹¼ºÉ¤Î¿´¶ÚÆâË즤ȳ°Ë즤ÎIBS¤òµÏ¿¤·¡¢¤½¤ÎÊÑÆ°Î̤ÈÊÑÆ°¥Ñ¥¿¡¼¥ó¤ò²òÀϤ·¡¢¿´¶ÚÆâË즤ȳ°Ë즤ÎIBS¤Èº¸¼¼·ÁÂ֤ȤδØÏ¢¤Ë¤Ä¤¤¤Æ¸¡Æ¤Ãæ¤Ç¤¢¤ê¡¢¤½¤Î·ë²Ì¤Î°ìÉô¤òÊó¹ð¤·¤¿¡£¤Þ¤¿¡¢¿´³°Ëì»éËÃÄÀÃ夬¿´µ¡Ç½¤ËµÚ¤Ü¤¹±Æ¶Á¤Ï¸¡Æ¤¤µ¤ì¤Æ¤¤¤Ê¤¤¡£MRI¡¢¿´¥¨¥³¡¼¿Þ¤òÍѤ¤¤Æ¿´³°Ëì»éËäÎÄêÎÌɾ²Á¤ò¹Ô¤¤¡¢¿´³°Ëì»éËÃÄÀÃ夬º¸¼¼³Èĥǽ¤Ë¤ª¤è¤Ü¤¹±Æ¶Á¤ò¸¡Æ¤Ãæ¤Ç¤¢¤ë¡£¤µ¤é¤Ë»éËÃÄÀÃå·²¤Î¿´¶ÚÁÈ¿¥À¾õ¿ÇÃǤòIBS¤Ë¤Æ²òÀϤ·fatty heart ¤Î³µÇ°¤ò³ÎΩ¤¹¤ë¤³¤È¤òÌÜŪ¤È¤·¤Æ¸¡Æ¤¤ò²Ã¤¨¤Æ¤¤¤ë¡£
£·¡¥½Û´Ä´ïÎΰè¤Ë¤ª¤±¤ë´Ñ·ìŪ¸¡ººË¡¤ª¤è¤Ó¼£ÎÅË¡¤Ë´Ø¤¹¤ë¸¡Æ¤
¡¡´§Æ°Ì®¼À´µ¤òÂоݤȤ·¡¢´§Æ°Ì®¹Å²½¡¢·ÐÈéŪ´§Æ°Ì®·ÁÀ®½Ñ(PTCA)¸å¤ÎºÆ¶¹ºõ¤ò¥Æ¡¼¥Þ¤ËÎ×¾²¸¦µæ¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£¼ç¤ËÄêÎÌŪ´§Æ°Ì®²òÀϤäðôư̮ÆâͲ»Çȸ¡ºº¤«¤éÆÀ¤é¤ì¤¿½ô»ØÉ¸¤ò¤â¤È¤Ë°Ê²¼¤Î¤è¤¦¤Ê¸¡Æ¤¤ò¹Ô¤¤¡¢°ìÉô¤Î·ë²Ì¤òÊó¹ð¤·¤¿¡£
¡¡¡¡1)StentÆâºÆ¶¹ºõ¤Ë´Ø¤ï¤ë½ô°ø»Ò(vWF¡¢ACE°äÅÁ»Ò¿·¿¡¢¥Ð¥¤¥ª¥Ô¥ê¥ó)¤Î¸¡Æ¤
¡¡¡¡2)Stent¸å¤Î°¡µÞÀ´§Êĺɤ˴ؤï¤ë¶Å¸ÇÀþÍÏ·Ï¤ÎÆ°Â֤˴ؤ¹¤ë¸¡Æ¤
¡¡¡¡3)´§·ì¹ÔºÆ·ú¤¬¿´¶ÚViability¤ª¤è¤Ü¤¹±Æ¶Á
£¸¡¥½Û´Ä´ï¼À´µ¤Î¥Ç¡¼¥¿¥Ù¡¼¥¹¹½ÃÛ
¡¡Evidence-based Medicine¤ÎÉáµÚ¤Ëȼ¤¤¡¢½¾Íè¤Î¥á¥«¥Ë¥º¥à¤Î¤ß¤Ë´ð¤Å¤¯°åÎŤè¤ê¡¢»àË´¤Ê¤É´µ¼Ô¤Ë¤È¤Ã¤Æ½ÅÍפÊoutcome¤ò¼ÂºÝ¤Ë¸º¾¯¤µ¤»¤ë»ö¤¬¾ÚÌÀ¤µ¤ì¤¿°åÎŤ¬½ÅÍ׻뤵¤ì¤Æ¤¤Æ¤¤¤ë¡£¤½¤Î¤¿¤á¤Î¥Ç¡¼¥¿¥Ù¡¼¥¹¤È¤·¤ÆµÞÀ¿´¶Ú¹¼ºÉ¤Ë¤è¤ë»àË´¡¢Ã×»àÀÉÔÀ°Ì®¤Ë¤è¤ë»àË´¡¢¿´Ë¼ºÙư¤Ëȼ¤¦·ìÀòºÉÀò¾É¤Îȯ¾É¡¢Brugada¾É¸õ·²¤Îͽ¸å¤Ê¤É¤Î½Û´Ä´ï¼À´µ¤Ë¤ª¤±¤ë½ÅÍפʴµ¼Ôoutcome¤Ë¤Ä¤¤¤Æ¤Î¥Ç¡¼¥¿¥Ù¡¼¥¹¤ò¹½ÃÛ¤·¡¢°ìÉô¤Î·ë²Ì¤òÊó¹ð¤·¤¿¡£
£¹¡¥Ç¾ÀÍøÇ¢¥Ú¥×¥Á¥É(BNP)¤ÎÎ×¾²±þÍѤˤĤ¤¤Æ¤Î¸¡Æ¤
¡¡·ìÞùǾÀÍøÇ¢¥Ú¥×¥Á¥É(BNP)Ãͤϡ¢¿´ÉÔÁ´¤Î¥Þ¡¼¥«¡¼¤È¤·¤Æ¹¤¯Î×¾²±þÍѤµ¤ì¤Æ¤¤¤ë¤¬¡¢Î×¾²½ê¸«¤È¤ÎÉÔ°ìÃפ⤷¤Ð¤·¤Ðǧ¤á¤é¤ì¤ë¡£BNPÃͤÎÎ×¾²±þÍѤˤĤ¤¤Æ¡¢¤½¤Î͸úÀ¤È¸Â³¦¤Ë¤Ä¤¤¤Æ³Æ¼ï¤Î½Û´Ä´ï¼À´µ¤Ë¤Æ¸¡Æ¤¤·¡¢°ìÉô·ë²Ì¤òÊó¹ð¤·¤¿¡£¤Þ¤¿¡¢¿´Ë¼ÀBNP¤È¿´¼¼ÀBNP¤È¤Îº¹¤Ë¤Ä¤¤¤Æ¤â¸¡Æ¤Ãæ¤Ç¤¢¤ë¡£
ÆâʬÈ硦Âå¼Õ
1. ÆâʬÈç
¡¡¡¡ÆâʬÈ硦¹Ã¾õÁ£³°Íè¡¢ÆâʬÈ硦Âå¼Õ³°Íè¤Ç¡¢¹Ã¾õÁ£¼À´µ¤ò¤Ï¤¸¤á¤È¤¹¤ë¼ï¡¹¤ÎÆâʬÈ硦Âå¼Õ¼À´µ´µ¼Ô¤Î¿ÇÎŤò¹Ô¤¦¤È¶¦¤Ë¡¢¤³¤ì¤é¤ÎÎ×¾²Åª¤Ê¤é¤Ó¤Ë¼Â¸³Åª¸¦µæ¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£
¡¡
¡¡¹Ã¾õÁ£¥Û¥ë¥â¥óºîÍÑȯ¸½¤Ëɬ¿Ü¤Î¹ÚÁǤǤ¢¤ë1·¿µÚ¤Ó2·¿Ã¦¥è¡¼¥É¹ÚÁǤΰäÅÁ»Òȯ¸½Ä´Àᵡ½ø¤ò¥Ò¥ÈµÚ¤Ó¥Þ¥¦¥¹¤ä¥é¥Ã¥È¤Î¼ï¡¹Â¡´ï¤òÍѤ¤¤Æ¸¦µæ¤·¤Æ¤¤¤ë¡£ÆÃ¤Ë¡¢¥Ò¥È¹Ã¾õÁ£¤Ç¤Ï¡¢¥é¥Ã¥È¤È°Û¤Ê¤ê¡¢£±·¿¤Î¤ß¤Ê¤é¤º¡¢£²·¿Ã¦¥è¡¼¥É¹ÚÁǤâȯ¸½¤·¤Æ¤¤¤ë¤³¤È¤òÌÀ¤é¤«¤Ë¤·¤¿¡£¤½¤·¤Æ¡¢¥Ò¥È¹Ã¾õÁ£¤Î£±·¿¤È£²·¿¤ÎËܹÚÁÇ¤Ë¤ÏÆÈ¼«¤Îȯ¸½Ä´Àᵡ¹½¤¬¤¢¤ê¡¢À¸ÂΤιþõÁ£¥Û¥ë¥â¥ó³èÀ²½¤Ë¤³¤ì¤é¤¬¶¨Ä´¤·¤Æ´ØÍ¿¤·¤Æ¤¤¤ë¤³¤È¤òÊó¹ð¤·¤¿¡£¹¹¤Ë¡¢¥Ò¥ÈÂçÆ°Ì®·ì´ÉÊ¿³ê¶ÚºÙ˦¤Ë2·¿Ã¦¥è¡¼¥É¹ÚÁdzèÀµÚ¤ÓmRNA¤¬Â¸ºß¤¹¤ë¤³¤È¤ò¼¨¤·¡¢ËܹÚÁǤ¬·ì°µ¤Ê¤É¤Ë¤â´ØÍ¿¤·¤Æ¤¤¤ë²ÄǽÀ¤ò¼¨¤·¤¿¡£ËܹÚÁÇȯ¸½Ä´Àᵡ½ø¤ÎɾºÙ¤Ë¤Ä¤¤¤Æ¸¦µæÃæ¤Ç¤¢¤ë¡£¤Þ¤¿¡¢°À´ãµåÆÍ½Ð¾É¤Ë¤Ä¤¤¤Æ¡¢Î×¾²Åª¤Ë¥¹¥Æ¥í¥¤¥É¥Ñ¥ë¥¹ÎÅË¡¤ä¾È¼ÍÎÅË¡¤ò¹Ô¤¦¤È¶¦¤Ë¡¢¤½¤ÎÉÂÂÖ¤ò¸¦µæ¤·¤Æ¤¤¤ë¡£
2. ÅüÇ¢ÉÂ
¡¡ÅüǢɳ°Íè¤ò¼õ¿Ç¤¹¤ë´µ¼Ô¿ô¤Ïǯ¡¹Áý²Ã¤·¤Æ¤ª¤ê¡¢¤Þ¤¿¡¢Æþ±¡¤Ç¤Ï¡¢·ìÅü¥³¥ó¥È¥í¡¼¥ë¤äÅüǢɶµ°éÌÜŪ´µ¼Ô¤«¤é¡¢½Å¾É¹çÊ»¾É¤òͤ¹¤ë´µ¼Ô¤Î¼£ÎŤޤÇÉý¹¤¤´µ¼Ô¤Î¿ÇÎŤËÂбþ¤·¤Æ¤¤¤ë¡£ÅüǢɿÇÎŤκǶá¤ÎÆÃħ¤Ï¡¢¼ï¡¹¤Î¥¤¥ó¥¹¥ê¥óÀ½ºÞ¤Ë¤è¤ë¸·³Ê¤Ê·ìÅü¥³¥ó¥È¥í¡¼¥ëË¡¤ä¿·¤·¤¤ÆâÉþ¤ÎÌôʪ¼£ÎŤ¬¼ï¡¹³«È¯¤µ¤ì¤Æ¤¤¿¤³¤È¤Ç¤¢¤ë¡£¤³¤ì¤é¤Î´µ¼Ô¤òÂоݤˡ¢¸½ºß¤ª¤â¤ËÅüǢɴÉÍýµÚ¤Ó¹çÊ»¾É¤Îȯ¾É¡¦¿ÊŸÁ˻ߤΤ¿¤á¤ÎÎ×¾²Åª¸¦µæ¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£µ·¿ÅüǢɤˤª¤±¤ë¼À´µ´¶¼õÀHLA¥Ï¥×¥í¥¿¥¤¥×¤Î²òÀϤòÊó¹ð¤·¤¿¡£¤Þ¤¿¡¢ÅüǢɤˤª¤±¤ë·ì¾®Èĵ¡Ç½Ð¶¿Ê¤Î¥á¥«¥Ë¥º¥à¤Î²òÀϤȹçÊ»¾É¤Ø¤Î´ØÏ¢¤Ë¤Ä¤¸¡Æ¤¤·¤Æ¤ª¤ê¡¢Ã±µå¤ª¤è¤Ó·ì¾®ÈijèÀ²½¥Þ¡¼¥«¡¼¤ÎưÂ֤ˤĤ¤¤ÆÊó¹ð¤·¤Æ¤¤¤ë¡£¤µ¤é¤Ë¡¢³Æ¼ïÀÜÃåʬ»Ò¤Î¬Äê (VCAM-1, ICAM-1, P-selection) ¤ò¹Ô¤¤¡¢¹³·ì¾®ÈĺÞÅêÍ¿¤Î¸ú²Ì¤Ë¤Ä¤¤¤ÆÎ×¾²Åª¸¦µæ¤ò¹Ô¤Ê¤Ã¤Æ¤¤¤ë¡£
3¡¥ÅüǢɤδðÁø¦µæ
¡¡ÅüÇ¢ÉÂʬÌî¤Ç¤Î´ðÁø¦µæ¤È¤·¤Æ¤Ï¡¢ÅüÇ¢ÉÂÀ¹çÊ»¾É¤ÎÀ®°ø¤òÌÀ¤é¤«¤Ë¤¹¤ë¤³¤È¤òÌÜŪ¤Ë¸¦µæ¤ò¤ª¤³¤Ê¤Ã¤Æ¤¤¤ë¡£¤³¤ì¤Þ¤ÇÅüÇ¢ÉÂÀ¹çÊ»¾É¤Î¿ÊŸ°ø»Ò¤È¤·¤Æ¤Ï¥Ý¥ê¥ª¡¼¥ë·ÏÂå¼Õ¡¢£Ã¥¥Ê¡¼¥¼³èÀ¡¢Åü²½ÃÁÇò¤ª¤è¤Ó»À²½¥¹¥È¥ì¥¹¤Ê¤É¤Î´ØÍ¿¤¬Êó¹ð¤µ¤ì¤Æ¤¤¤ë¡£¸½ºß²æ¡¹¤ÏÅü²½ÃÁÇò¤Î¼õÍÆÂΤΤҤȤĤǤ¢¤ëRAGE (receptor for advanced glycation endproducts) ¤Î¥·¥°¥Ê¥ëÅÁãÍͼ°¤Î²òÌÀ¤ª¤è¤Ó¡¢¤½¤Î¿·µ¬¥ê¥¬¥ó¥É¤Ç¤¢¤ëS100´ØÏ¢ÃÁÇò¤ÎÅüÇ¢ÉÂÀ¹çÊ»¾É¤Ø¤Î´ØÍ¿¤ò¡¢Ê¬»ÒÀ¸Êª³ØÅª¼êË¡¤òÍѤ¤¸¡Æ¤¤·¤Æ¤¤¤ë¡£
¿Õ¡¡Â¡¡¦·ì±ÕÆ©ÀÏ
1.¡¡¥Æ¥¤¥é¡¼¥á¥¤¥É°åÎŤò¤á¤¶¤·¤¿ÀèÅ·À¿ÕÀÇ¢Êø¾É²È·Ï¤Î°äÅÁ»Ò²òÀÏ
¡¡ÀèÅ·À¿ÕÀÇ¢Êø¾É¤ÏÀèŷŪ¤Ê¿ÕÇ¢ºÙ´É¤Ç¤Î¥Ð¥½¥×¥ì¥·¥ó(AVP)ÉÔ±þÀ¤Ë¤è¤êǢǻ½Ì¾ã³²¤òµ¯¤³¤¹¼õÍÆÂΰ۾ï¾É¤Ç¤¢¤ë¡£»äã¤ÏËÜË®¤Ë¤ª¤¤¤Æ10²È·Ï¤ÎAVP¼õÍÆÂΰäÅÁ»ÒÇÛÎó¤ò¸¡Æ¤¤·¡¢É°ø¤È¤Ê¤ë°äÅÁ»Ò°Û¾ï¤ò½é¤á¤ÆÊó¹ð¤·¤¿¡£¤µ¤é¤ËCHOºÙ˦¤ËÄê¾ïȯ¸½¤µ¤»¤ë¤³¤È¤Ë¤è¤êµ¡Ç½°Û¾ï¤òºÆ¸½¤·È¯¾É¤Îʬ»Òµ¡¹½¤ò²òÌÀ¤·¤¿¡£
2.¡¿ÕÀ¸¸¡Áü¤«¤é¤ß¤¿¿Õ±ê¡¦¥Í¥Õ¥í¡¼¥¼¾É¸õ·²¤Î¼£ÎŤª¤è¤Óͽ¸å¤Ë±Æ¶Á¤¹¤ë°ø»Ò¤Î¸¡Æ¤
¡¡¿Õ¼À´µ¤Ë¤ª¤±¤ëÎ×¾²Åª¸¦µæ¤È¤·¤Æ¡¢¤³¤ì¤Þ¤ÇËìÀ¿Õ¾É¤Î¼£ÎŤª¤è¤Óͽ¸å¤Ë´Ø¤¹¤ë°ø»Ò¤Ë¤Ä¤¤¤Æ¿ÕÁÈ¿¥Áü¤«¤é¤Î¸¡Æ¤¤ò¹Ô¤Ã¤Æ¤¤¿¡£º£¸å¤Ï¡¢¤ï¤¬¹ñ¤ÇºÇ¤â¿¤¤¸¶È¯À»åµåÂοձê¤Ç¤¢¤ëIgA¿Õ¾É¤Î¿ÕÀ¸¸¡ÁÈ¿¥¤â¸¡Æ¤¤·¤Æ¤¤¤¯Í½Äê¤Ç¤¢¤ë¡£´ðÁÃʬÌî¤Ç¤Ï¿ÕÀþ°Ý²½¤Ë¤ª¤±¤ë¥á¥µ¥ó¥®¥¦¥à¤ª¤è¤Ó¿ÕÇ¢ºÙ´ÉºÙ˦¤ËÂФ¹¤ë¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥ó¶¤ÎºîÍѵ¡½ø¡¢ÆÃ¤ËÀ®Ä¹°ø»Ò¤ò²ð¤·¤¿ºÙ˦ÆâÅÁ㵡¹½¤ò¼ç´ã¤È¤·¤¿¸¦µæ¤ò¹Ô¤Ã¤¿¡£Î×¾²Ê¬Ìî¤Ç¤Ï¡¢ËýÀ¿ÕÉÔÁ´¤Î·ì°µ´ÉÍý¤Ë¤ª¤±¤ë¦Á¼×ÃÇÌô¤Î°ÌÃÖÉÕ¤±¤Ë´Ø¤¹¤ë¸¡Æ¤¤Ê¤é¤Ó¤Ë¥Ñ¥ë¥Ü¥¦¥£¥ë¥¹¤Ë¤è¤ëµÞÀ¿Õ±ê¤ÎÎ×¾²ÅªÆÃħ¤Ë¤Ä¤¤¤Æ²òÀϤ·¤¿¡£
¡¡¢Ç¢ºÙ´ÉºÙ˦¤Ë¤ª¤±¤ëTGF-¦Â¤ÎºÙ˦ÆâÅÁ㵡¹½
¿¤¯¤ÎËýÀ¿Õ¼À´µ¤Î¿ÊŸ¤ÏÇ¢ºÙ´É´Ö¼ÁÉÂÊѤˤè¤ë¡£¤½¤Îkey molecule¤Ç¤¢¤ëTGF-¦Â¤Ë¤Ä¤¤¤Æ¡¢Ç¢ºÙ´ÉºÙ˦¤Ë¤ª¤±¤ëºÙ˦Æâ¾ðÊóÅÁ㵡½ø¤ò¸¡Æ¤¤·¤Æ¤¤¤ë¡£
3. ·ì±ÕÆ©ÀÏ
¡¡Æ©Àϼ¼¤Ç¤Ï¡¢Âè2Æâ²Ê¤Î´µ¼Ô¤ò¤Ï¤¸¤á¡¢¼ï¡¹¹çÊ»¾É¤òµ¯¤³¤·¤ÆÆþ±¡¤·¤¿±¡Æâ³Æ²Ê¤Î´µ¼Ô¤òÆ©ÀϤ·¤Æ¤¤¤ë¡£¤Þ¤¿¡¢²È²À¹â¥³¥ì¥¹¥Æ¥í¡¼¥ë·ì¾É´µ¼Ô¤ä¿Õ¼À´µ´µ¼Ô¤ËLDL¥¢¥Õ¥§¥ì¡¼¥·¥¹¤ò»Ü¹Ô¤·¤¿¤ê¡¢¼ï¡¹¤Î·ìÞù¸ò´¹ÎÅË¡¤â¹Ô¤Ã¤Æ¤¤¤ë¡£»ý³ʢËìÆ©ÀÏ(CAPD)´µ¼Ô¤âÁý²Ã¤·¤¿¡£·ì±ÕÆ©ÀÏ´µ¼Ô¤ÎƳÆþ´ü¡¢µÚ¤ÓËýÀ´ü¤Î¹çÊ»¾É¤Ë¤Ä¤¤¤Æ¡¢ÆÃ¤Ë¡¢Æ©ÀÏ´µ¼Ô¤Î¹Ã¾õÁ£µ¡Ç½¤ä·ìÃæ¹Ã¾õÁ£¥Û¥ë¥â¥ó°Û¾ï¡¢Éû¹Ã¾õÁ£°Û¾ï¤Ê¤ÉÆâʬÈç°Û¾ï¤Î´ØÏ¢¤Ë¤Ä¤¤¤Æ¸¡Æ¤¤·¤Æ¤¤¤ë¡£¤Þ¤¿¡¢ÅüǢɿվɤÎȯ¾É¤È¿ÊŸ¤Ë´Ø¤¹¤ë¸¦µæ¤ò¹Ô¤Ã¤Æ¤¤¤ë¡£¹¹¤Ë¡¢¶¹¿´¾É¡¦¿´¶Ú¹¼ºÉ¤Ê¤É¤Î´§Æ°Ì®¼À´µ¹çÊ»¤Ë´Ø¤·¤Æ¡¢Â¿¤¯¤Î´µ¼Ô¤òÂоݤȤ·¤ÆÎ×¾²Åª¸¦µæ¤ò³¤±¤Æ¤¤¤ë¡£
¹â·ì°µ¡¦Æ°Ì®¹Å²½¡¦Âå¼Õ
£±. ºÙ˦°Ü¿¢¡¦°äÅÁ»Ò¼£ÎŤˤè¤ëư̮¹Å²½À¿´·ì´Éɤˤª¤±¤ë·ì´É¿·À¸¤òÌÜŪ¤È¤·¤¿ºÆÀ¸°åÎÅ
¡¡¹ü¿ññ³ËµåºÙË¦Ãæ¤Ë¤Ï·ì´ÉÆâÈéÁ°¶îºÙ˦¤¬Â¸ºß¤·¡¢¿´¶Ú¤ä²¼»è¹ü³Ê¶Ú¤Îµõ·ìÁÈ¿¥¤Ë¤ª¤¤¤Æ¤³¤ÎÆâÈéÁ°¶îºÙ˦¤Ï·ì´É¿·À¸¤òͶƳ¤¹¤ë¤³¤È¤ò´ðÁü¸³¤è¤êÌÀ¤é¤«¤Ë¤·¤¿¡£´ØÀ¾°åÂçÎÑÍý°Ñ°÷²ñ¤Î¾µÂú¤òÆÀ¤Æ¡¢2000ǯ7·î14Æü¤Ë²¼»èÊĺÉÀư̮¹Å²½¾É¤Î´µ¼Ô¤µ¤ó¤Ë¡¢¼«¸Ê¹ü¿ññ³ËºÙ˦¤ò°Ü¿¢¤·Í¸ú¤Ê·ì´É¿·À¸¡¦¼«³Ð¾É¾õ¤Î²þÁ±¤òǧ¤á¤¿¡£°Ê¸å¡¢45¿Í¤Îµõ·ì»è´µ¼Ô¤µ¤ó¤Ë¼Â»Ü¤·¤¿¡£2001ǯ12·î19Æü¤Ë½Å¾Éµõ·ìÀ¿´¼À´µ¾ÉÎã¤Ë¼Â»Ü¤·¤¿¡£¿´Çï½ÐÎ̤¬Áý²Ã¤·¡¢¶»Äˤâ¾Ã¼º¤·¤¿¡£¹ü¿ññ³Ëµå°Ü¿¢¤òÍѤ¤¤¿·ì´É¿·À¸¼£ÎŤÏÁ´¹ñ22Âç³ØÉ±¡¤ÇºÎÍѤµ¤ì¡¢»ä㤬³ÎΩ¤·¤¿¥×¥í¥È¥³¡¼¥ë¤¬ºÎÍѤµ¤ì¤Æ¤ª¤ê¡¢º£¸å¤³¤ÎºÆÀ¸°åÎŤÎÃæ¿´»ÜÀߤȤ·¤Æµ¡Ç½¤¹¤ë¤È¹Í¤¨¤é¤ì¤ë¡£
£²¡¥°äÅÁ»Ò¹©³Ø¤òÍѤ¤¤¿·ì´ÉºîƯÀʪ¼Á¡Ê¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥óII¡¦¥«¥Æ¥³¥é¥ß¥ó¡ËºîÍѤÎʬ»Ò¡¦¸ÄÂÎ¥ì¥Ù¥ë¤Ç¤Î²òÀϤȼõÍÆÂΤÎȯ¸½Ä´Àá
¡¡°äÅÁ»Ò¹©³Ø¤òÍѤ¤¤Æ·ì´ÉºîƯÀʪ¼Á¼õÍÆÂΤηì´ÉÊ¿³ê¶ÚÆÃ°ÛŪ¤¢¤ë¤¤¤Ï¿´¶ÚÆÃ°ÛŪ²á¾êȯ¸½¥È¥é¥ó¥¹¥¸¥§¥Ë¥Ã¥¯¥Þ¥¦¥¹¤òºîÀ½¤·¡¢¸ÄÂÎ¥ì¥Ù¥ë¤Ç¤Î¿´·ì´ÉºîÍѤòÌÀ¤é¤«¤Ë¤·¤Æ¤¤¿¡£
£³.¡¡¥Æ¥¤¥é¡¼¥á¥¤¥É°åÎŤò¤á¤¶¤·¤¿ÀèÅ·À¿ÕÀÇ¢Êø¾É²È·Ï¤Î°äÅÁ»Ò²òÀÏ
¡¡ÀèÅ·À¿ÕÀÇ¢Êø¾É¤ÏÀèŷŪ¤Ê¿ÕÇ¢ºÙ´É¤Ç¤Î¥Ð¥½¥×¥ì¥·¥ó(AVP)ÉÔ±þÀ¤Ë¤è¤êǢǻ½Ì¾ã³²¤òµ¯¤³¤¹¼õÍÆÂΰ۾ï¾É¤Ç¤¢¤ë¡£»äã¤ÏËÜË®¤Ë¤ª¤¤¤Æ10²È·Ï¤ÎAVP¼õÍÆÂΰäÅÁ»ÒÇÛÎó¤ò¸¡Æ¤¤·¡¢É°ø¤È¤Ê¤ë°äÅÁ»Ò°Û¾ï¤ò½é¤á¤ÆÊó¹ð¤·¤¿¡£¤µ¤é¤ËCHOºÙ˦¤ËÄê¾ïȯ¸½¤µ¤»¤ë¤³¤È¤Ë¤è¤êµ¡Ç½°Û¾ï¤òºÆ¸½¤·È¯¾É¤Îʬ»Òµ¡¹½¤ò²òÌÀ¤·¤¿¡£
¡Ô¸¦µæ¶ÈÀÓ¡Õ
¸¶¡¡¡¡Ãø
- Tsuka Y, Sugiura T, Hatada K, Nakamura S, Yuasa F and Iwasaka T (2001)
Clinical significance of ST-segment elevation in lead V1 in patients with acute inferior wall Q-wave myocardial infarction.
Am Heart J 141:615-620
- Hamada S, Nakamura S, Sugiura T, Nishiue T, Watanabe J, Hatada K, Miyoshi H, Baden M and Iwasaka T (2001)
Accuracy of technetium-99m tetrofosmin myocardial perfusion imaging in the detection of spontaneous recanalization in patients with acute anterior myocardial infarction.
Eur J Nucl Med 28:326-333
- Hamada S, Nishiue T, Nakamura S, Sugiura T, Kamihata H, Miyoshi H, Imuro Y and Iwasaka T (2001)
TIMI frame count immediately after primary coronary angioplasty as a predictor of functional recovery in patients with TIMI 3 reperfused acute myocardial infarction.
J Am Coll Cardiol 38:666-671
- Watanabe J, Nakamura S, Sugiura T, Takehana K, Hamada S, Miyoshi H, Saito D, Hatada K, Kurihara H, Baden M and Iwasaka T (2001)
Early identification of impaired myocardial reperfusion with serial assessment of ST segments after percutaneous transluminal coronary angioplasty during acute myocardial infarction.
Am J Cardiol 88:956-959
- Hatada K, Sugiura T, Kamihata H, Nakamura S, Takahashi N, Yuasa F and Iwasaka T (2001)
Clinical significance of coronary flow to the infarct zone before successful primary percutaneous transluminal coronary angioplasty in acute myocardial infarction.
Chest 120:1959-1963
- Sugiura T, Yamasaki F, Hatada K, Nakamura S and Iwasaka T (2001)
Correlates of bundle-branch block in patients undergoing primary angioplasty for acute myocardial infarction.
Clin Cardiol 24:770-774
- Tokunaga S, Tsuji H, Nishiue T, Yamada K, Miyasaka Y, Saitou D and Iwasaka T (2001)
Lower mortality in patients with the DD genotype of the
Angiotensin - converting enzyme gene after acute myocardial infarction.
Acta Cardiolol 56:351-355
- Miyasaka Y, Tsuji H, Yamada K, Tokunaga S, Saito D, Imuro Y, Matsumoto
N and Iwasaka T (2001)
Prevalence and mortality of the Brugada-type
electrocardiogram in one city in Japan.
J Am Coll Cardiol 38:771-774
- Miyoshi H, Takayama Y, Tamura T,Kitashiro S,Izuoka T, Saito D, Imuro Y and
Iwasaka T(2001)
Regional myocardial function at the papillary muscle
Insertion site.
Jpn J Physiol 51:109-114
- Takehana K, Sugiura T, Nagahama Y, Hatada K,Okugawa S and Iwasaka T
(2000)
Cardiovascular response to combined ststic-dynamic exercise of
patients with myocardial infarction.
Coron Artery Dis 11:35-40
- Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Tsutsumi Y, Ozono R,
Masaki H, Mori Y, Iba O, Tateishi E, Kosaki A, Shintani S,Murohara T,
Imaizumi T, Iwasaka T(2001)
Implantation of bone marrow mononuclear
cells into ischemic myocardium enhances collateral perfusion and regional
function via side supply of angioblasts, angiogenic ligands, and cytokines.
Circulation 104:1046-1052
- Hara K, Morita Y, Kamihata H, Iwasaka T and Takahashi H(2001)
Evidence for
Infection with helicobacter pylori in patients with acute myocardial infarction.
Clin Chim Acta 313:87-94
- Ohyama H, Kajita H, Omori K, Takumi T, Hiramoto N,Iwasaka T and Matsuda H
(2001)
Inhibition of cardiac delayed rectifier K+ currents by an antisense
oligodeoxynucleotide against lsK(minK) and over-expression of isK mutant
D77N in neonatal mouse hearts.
Eur J Physiol 442:329-335
- Morita Y, Takahashi H, Kamihata H, Yamamoto Y, Hara K and Iwasaka T(2001)
Urinary excretion of biopyrrins, oxidative metabolites of bilirubin, increases
after spasm provocation tests in patients with coronary spastic angina.
Cardiology 80:243-250
- Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y,
Masaki H, Uchiyama Y, Koyama Y, Nose, Iba O, Tateishi E, Ogata N.
Jyo N, Higashiyama S and Iwasaka T(2001)
Angiotensin AT1 and AT2 receptors
differentially regulate angiopoietin-2 and vascular endothelial growth
factor expression and angiogenesis by modulating heparin binding-epidermal
growth factor(EGF) -Mediated EGF receptor transactivation.
Circ Res
88:22-29
- Uchiyama-Tanaka Y, Matsubara H, Nozawa Y, Murasawa S, Mori Y, Kosaki A,
Maruyama K, Masaki H, Shibasaki Y, Fujiyama S, Nose A, Iba O, Hasegawa T,
Tateishi E, Higashiyama S and Iwasaka T (2001)
Angiotensin II signaling and HB-
EGF shedding via metalloproteinase in glomerular mesangial cells.
Kidney Int
60: 2153-2163
- Mori Y, Matsubara H, Nose A, Shibasaki Y, Masaki H, Kosaki A, Ikigaki N,
Fujiyama S, Tanaka-Uchiyama Y, Hasegawa T, Iba O, Tateishi E, Amano K and
Iwasaka T (2001)
Safety and availability of doxazosin in treating hypertensive
patients.
Hypertens Res 24: 359-366
- Shibasaki Y, Matsubara H, Nozawa Y, Mori Y, Masaki H, Kosaki A, Tsutsumi
Y, Uchiyama Y, Fujiyama S, Nose A, Iba O, Tateishi E, Hasegawa T, Horiuchi
M, Nahmias C and Iwasaka T (2001)
Angiotensin II Type 2 Receptor Inhibits EGF
Receptor Transactivation by Increasing Association of SHP-1 TyrosinePhosphatase
Hypertension 38:367-372
- Nakagami H, Morishita R, Yamamoto K, Yoshimura S, Taniyama Y, Aoki M,
Matsubara H, Kim S, Kaneda Y and Ogihara T (2001)
Phosphorylation of p38
mitogen-activated protein kinase downstream of bax-caspase-3 pathway leads to
cell death induced by high D-glucose in human endothelial cells.
Diabetes 50:1472-1481
- Matsubra H(2001)
Renin-angiotensin system in human failing hearts: message
From nonmyocyte cells to myocytes.
Circ. Res 88:861-863
- Fujiyama S, Matsubara H, Mori Y, Masaki H, Tsutsumi Y, Shibasaki Y,
Kitabayashi I, Uchiyama Y, Iba O and Iwasaka T (2001)
Angiotensin AT1 and AT2
Receptors Differentially Regulate Angiopoietin 2 Expression and VEGF
Expression and Angiogenesis by Modulating Heparin Binding EGF-Mediated
EGF Receptor Transactivation.
Circ.Res 88:22-29
- Hattori R, Otani H, Moriguchi Y, Matsubara H, Yamamura T, Nakao Y, Omiya H,
Osako M and Imamura H(2001)
NHE and ICAM-1 expression in hypoxic/reoxygenated
coronary microvascular endothelial cells.
Am J Physiol Heart Circ Physiol 280:H2796-2803
- Imai Y, Toyoda N, Maeda A, Kadobayashi T, Wang F, Kuma K, Nishikawa M and
Iwasaka T (2001)
Type 2 iodothyronine deiodinase expression isupregulated by the
protein kinase A-dependent pathway and is downregulated by the protein kinase
C-dependent pathway in cultured human thyroid cells.
Thyroid 11: 899-907
- Tashima S, Kimura Y and Okuda T (2001)
Assessment of local body composition by
near infrared interactance(NIR).
Body Composition 7¡§11-13
- ȪÅÄ·û¸ã¡¢¿ù±ºÅ¯Ï¯¡¢ÃæÂ¼À¿»Ö¡¢±º¾å¾»Ìé¡¢´äºäÔèÆó (2001)
¿´¶Ú¹¼ºÉȯ¾É»þ¤Ë¤ß¤é¤ì¤ëÓÒµ¤¡¦ÓÒÅǤÎÎ×¾²Åª°ÕµÁ.
Æü½¸Ãæ¼£ÎŰå²ñ»ï 8:97-101
- »³ËÜů»Ë¡¢ÃæÃ« Àµ¡¢µ®Åçϵס¢²ÏÌî·¼»Ò¡¢¿¹ÅÄ Å¯¡¢¾®»å¿Î»Ë¡¢Ë ¹É¡¢µÜºäÍÛ»Ò¡¢ÃæÂ¼À¿»Ö¡¢´äºäÔèÆó¡¢¿¢Â¼Ë§»Ò(2001)
¿´¥¨¥³¡¼¾å³ÈÄ¥·¿¿´¶Ú¾ÉÍͤÎÊѲ½¤òÍ褷¤¿ Multicentric Castleman¡Çs Disease ¤Î1Îã.
ÆüÆâ²ñ»ï¡¡90:123-126.
- ÄÔ µ×»Ò¡¢°æ¾å Ű¡¢±àÆ£ÍÛ»Ò¡¢ËÌÀî¹á¿¥¡¢ÌÚ¸¶ ͵ (2001)
Î×¾²±Ö³Ø¤òÂêºà¤È¤·¤¿¼ÂÁ©Åª¤Ê°å³ØÅý·×½èÍý±é½¬¤Î»î¤ß¤È¤½¤Îɾ²Á.
Ê¿À®13ǯÅÙ¾ðÊó½èÍý¶µ°é¸¦µæ½¸²ñ¹Ö±éÏÀʸ½¸¡Ê¼çºÅ¡§Ê¸Éô²Ê³Ø¾Ê¡¦Ï²λ³Âç³Ø¡Ë245-248
- »°¹¥¹Åµ, ÀÆÆ£Âç¼ù, ȪÅÄ·û¸ã, ¿ÀÈ«¡¡¹¨, ¿¹ÅÄ¡¡´², °Ë¼¼Í´²ð, ßÀÅÄ¿®°ì¡¢µÜºäÍÛ»Ò, ´äºäÔèÆó(2001)
¿´ÅÅ¿ÞÊѲ½¤ò¤È¤â¤Ê¤ï¤Ê¤¤¶»ÄËȯºî.
¥Ï¡Ý¥È¥Ê¡Ý¥·¥ó¥° 14:57-60
- ßÀÅÄ¿®°ì¡¢¾¾ËÜŵ»Ò, µÜºäÍÛ»Ò, »þ²¬¿¿Íý, ¾®¾¾¡¡¹á, ÄÍ Ë§ÌÀ¡¢¿¹ÅÄ¡¡´²,¿ÀÈ«¡¡¹¨, »³Ëܹî¹À, ÀÆÆ£Âç¼ù, »°¹¥¹Åµ, °Ë¼¼Í´²ð, Â绳½¨É×,´äºäÔèÆó (2001)
QRS¤¬¹¤¤¿´Åſޤò¼¨¤¹¶»ÄËȯºî¤Î1Îã.
¥Ï¡Ý¥È¥Ê¡Ý¥·¥ó¥° 14:44-46
- ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢ÀÆÆ£Âç¼ù, »°¹¥¹Åµ, »³Åĸ÷°ì, Åò»³ÎáÊå, ̣¼¡¡½ã,ßÀÅÄ¿®°ì¡¢´äºäÔèÆó(2001)
99mTechnetium ¥Ô¥í¥ê¥ó»À¿´¶Ú¥·¥ó¥Á¥°¥é¥Õ¥£¤Ë¤è¤êÁá´ü³ÎÄê¿ÇÃǤ˻ê¤Ã¤¿¿´¥¢¥ß¥í¥¤¥É¡¼¥·¥¹¤Î°ìÎã.
Osaka Heart Club 24:6-12
- »³ËÜů»Ë¡¢¿¹¡¡ÂÙÀ¶, ǽÀªÆØ»Ò, ¾¾¸¶¹°ÌÀ, ´äºäÔèÆó(2001)
¶õIJÀü¹¦¤ò¤¤¿¤·¤¿Á´¿ÈÀ¥³¥ì¥¹¥Æ¥í¡¼¥ëºÉÀò¾É¤Î1˶¸¡Îã.
Lipid 11:89-94
- Åò»³ÎáÊå, ÅòÀõʸͺ, ɧºä¡¡À¿, ̣¼¡¡½ã, ¸µ×¢¾Ç·, ¿ù±ºÅ¯Ï¯, ´äºäÔèÆó (2001)
ËýÀ¿´ÉÔÁ´¤Ë¤ª¤±¤ëÈ¿ÉüÀrhythmic handgrip »þ¤Î¶Ú¸ò´¹¿À·Ð³èư¤Î¸¡Æ¤.
¿´Â¡¡¡32:18-21
- ̣¼¡¡½ã, ÅòÀõʸͺ, ɧºä¡¡À¿, Åò»³ÎáÊå, ²Ï¼¹¸¹°, ßÀÅÄ¿®°ì¡¢¿ù±ºÅ¯Ï¯, ´äºäÔèÆó(2001)
ËýÀ¿´ÉÔÁ´¤Ë¤ª¤±¤ë±¿Æ°»þmetaboreflex¤ÈËö¾¿¸ò´¹¿À·Ð³èư¤Î¸¡Æ¤.
¿´Â¡ 33:95-97
- µÜºäÍÛ»Ò, º´µ×´Ö¹§Íº, ¾¾ËÜŵ»Ò, »þ²¬¿¿Íý, ¾®¾¾¡¡¹á, ÄÍ Ë§ÌÀ, ÀÆÆ£Âç¼ù, »°¹¥¹Åµ, °Ë¼¼Í´²ð, ´äºäÔèÆó(2001)
¹âÎð½÷À¤ÇÄã²¼¤ÈTÇÈÊ¿Äã²¼¤ò ǧ¤á¤¿°ìÎã.
¥Ï¡Ý¥È¥Ê¡Ý¥·¥ó¥° 14:14-16
- ̣¼¡¡½ã, ÅòÀõʸͺ, Åò»³ÎáÊå, ²Ï¼¹¸¹°, ´äºê¿¿²Â, ÆÁ±Ê¡¡ÃÒ, ´äºäÔèÆó(2001)
ËÜÂÖÀ¹â·ì°µ¾ÉÎã¤Ë¤ª¤±¤ë¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥ó¶¼õÍÆÂÎÙɹ³Ìô¤ÎÍÍÑÀ.
Osaka Heart Club 120:6-9
- ÌÚ¼¡¡¾÷(2001)
±¿Æ°ÎÅË¡»ØÆ³´ÉÍýÎÁ¤ÎŬ±þ³ÈÂç¤Ë¤ª¤±¤ëÎ×¾²¾å¤ÎÌäÂêÅÀ
Î×¾²±¿Æ°ÎÅË¡¸¦µæ²ñ»ï¡¡3¡§5-6
- ÌÚ¼¡¡¾÷¡¢´äºäÔèÆó(2001)
¥Ó¥¸¥å¥¢¥ë¥¹¥Æ¥Ã¥×¥¨¥¯¥µ¥µ¥¤¥º¤ÎÄê¾ï¿´Çï¿ôÍ»ÀÁDZ¿Æ°¤Ø¤Î±þÍÑ.
ÆüËÜ¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó³Ø²ñ»ï¡¡
6¡§59-61
- ÇϾìÅ·¿®¡¢ÌÚ¼¡¡¾÷¡¢º´Æ£¡¡¹ë (2001)
±¿Æ°ÎÅË¡¤Ë¤ª¤±¤ë¥«¥¦¥ó¥»¥ê¥ó¥°²ðÆþ¥·¥¹¥Æ¥à¤Î»î¤ß.
Î×¾²±¿Æ°ÎÅË¡¸¦µæ²ñ»ï¡¡3¡§23-29
- ÅÄÅ躴Ï»ҡ¢ÌÚ¼¡¡¾÷ (2001)
¥Ç¥¸¥¿¥ë¥«¥á¥é¤Ä¤·ÈÂÓÅÅÏäòÍøÍѤ·¤¿ÈîËþ¤Î¿©»ö»ØÆ³.
Î×±É 100¡§28-33
Áí¡¡¡¡Àâ
- ¿ù±ºÅ¯Ï¯¡¢»³ºêʸÌ÷¡¢ÃæÂ¼À¿»Ö¡¡(2001)
Î×¾²¸¡ºº¡¡³ÆÏÀ¡§Æâ²Ê°å¤È¤·¤ÆÃΤäƤª¤¯¤Ù¤¿·¤·¤¤¸¡ºº2. ½Û´Ä´ï·Ï¼À´µ.
ÆüÆâ³Ø»ï¡¡90:2206-2212.
- ÃæÂ¼À¿»Ö¡¢ßÀÅÄ¿®°ì¡¢ÄÍ Ë§ÌÀ¡¢´äºäÔèÆó (2001)
µÞÀ¿´ÉÔÁ´¤Î¿ÇÃǤοʤáÊý. ½Û´Ä´ï¼À´µver.2.
Ê̺ý°å¤Î¤¢¤æ¤ß¡¡194-196.
- ÄÔ¡¡µ×»Ò (2001)
¾ÉÎãÂоȸ¦µæ¤ÎÆÉ¤ßÊý¡¦¥Á¥§¥Ã¥¯¥ê¥¹¥È.
EBM¥¸¥ã¡¼¥Ê¥ë
2:632-636¡¡
- ´äºäÔèÆó (2001)
·ì´É¿·À¸ÎÅË¡.
Medical View Points 22:1
- ¾¾¸¶¹°ÌÀ, ¿ÀÈ«¡¡¹¨, À¾¾å¾°»Ö, Æ£»³Áí°ìϺ, ´äºäÔèÆó(2001)
¿´·ì´É·Ï¤ÎºÆ
À¸°åÎÅ.
Medical View Points 22:2
- ´äºäÔèÆó, µÜºäÍÛ»Ò, ¹âÅĸü¾È(2001)
ÆÃ½¸¡Ö¿´ÅſޤòÆÉ¤à¡×¶Æ¶ÀPÇȤÎ
¡¡ ·ÁÂ֤Ȱ۾ï1.ÇÈ·Á¡¦·ÁÂÖa.Àµ¾ï.
Heart View 5:22-23
- ÅòÀõʸͺ, Åò»³ÎáÊå, ̣¼¡¡½ã, ²Ï¼¹¸¹°, ´äºê¿¿²Â, ´äºäÔèÆó(2001)
Ϣ³
¡¡¡¡Åª¿´Çï½ÐÎÌ¥â¥Ë¥¿¥ê¥ó¥°. ¡¡
µßµÞ°å 25:785-788
- ¿ÝëÊÝÉס¢ÌÌÚ¹¨ (1999)
¿´¸¶À¥·¥ç¥Ã¥¯.
µßµÞ°å 23¡§1243-1246
- ¿ÀÈ«¡¡¹¨¡¢¾¾¸¶¹°ÌÀ¡¢´äºäÔèÆó (2001)
µõ·ìÀ¿´¼À´µ¤ËÂФ¹¤ë¼«²È¹ü¿ñ
ñ³ËµåºÙ˦°Ü¿¢¤òÍѤ¤¤¿·ì´É¿·À¸ÎÅË¡¤Î´ðÁÃŪ¸¡Æ¤.
½Û´Ä´ï°å¡¡9:199-207
- ¿ÀÈ«¡¡¹¨¡¢À¾¾å¾°»Ö¡¢»°¹¥¹Åµ¡¢ÀÆÆ£Âç¼ù¡¢°Ë¼¼Íµ²ð¡¢µÜºäÍÛ»Ò¡¢Æ£»³Áí
°ìϺ¡¢·ª¸¶ÍµÉ§¡¢ÄÍ¡¡Ë§ÌÀ¡¢¾¾ËÜŵ»Ò¡¢Î©ÀзÃΤ»Ò¡¢¾¾¸¶¹°ÌÀ¡¢´äºäÔèÆó
(2001)
¹ü¿ñºÙ˦°Ü¿¢¤Ë¤è¤ë·ì´É¿·À¸ÎÅË¡.
Med Technol 29:583-585
- ¾®ºêÆÆ»Ö¡¢¾¾¸¶¹°ÌÀ¡¢Ä¹Ã«ÀîδÀµ¡¢´äºäÔè¥Ë¡¡(2001)¡¡
ÅüÇ¢ÉÂÀ¿Õ¾É¤Î°ä
ÅÁÁǰø¡¡¥¢¥ó¥®¥ª¥Æ¥ó¥·¥Î¡¼¥²¥ó¡ÊM235T¡Ë¡¡
¿Õ¤ÈÆ©ÀÏ¡¡Î×»þÁý´©¹æ¡§
77-79
- À¸¿å ¹¸¡¢ÁáÀî ·É¡¢»°Âð Ë¡¢¹ñËܵÁ§¡¢À¾Àî¸÷½Å (2001)
ÅüÇ¢ÉÂ¤ÎÆ©ÀÏ´µ¼Ô¤Î±ÉÍÜ¡¦¿©»ö´ÉÍý.
Î×±É 99:882-885
³Ø²ñȯɽ
- ȪÅÄ·û¸ã¡¢ÃæÂ¼À¿»Ö¡¢ÃݲְìºÈ¡¢Åò»³ÎáÊ塢̣¼ ½ã¡¢ßÀÅÄ¿®°ì¡¢·ª¸¶ÍµÉ§¡¢
´äºäÔèÆó¡¢¿û Ë¡¢¿ù±ºÅ¯Ï¯ (2001)
Quantitative ECG-gated SPECT Image at
End-Diastole May More Accurately Estimate Myocardial Viability after Primary
PTCA in Patients with Myocardial Infarction.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ,
µþÅÔ
- Ê¡°æÀ¯·Ä¡¢ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢ßÀÅÄ¿®°ì¡¢·ª¸¶ÍµÉ§¡¢ÃݲְìºÈ¡¢ÇÏÅÂÀµ¿Í¡¢¿ù±ºÅ¯Ï¯¡¢´äºäÔèÆó¡¡(2001)
Early Prediction of the Final Infarct Size by
Scintigraphic Estimation of Myocardial Perfusion Immediately After Successful
Primary Coronary Angioplasty.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ,¡¡µþÅÔ
- ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢ÅÏî´½á»Ò¡¢ÃݲְìºÈ¡¢ßÀÅÄ¿®°ì¡¢·ª¸¶ÍµÉ§¡¢ÇÏÅÂÀµ
¿Í¡¢¿ù±ºÅ¯Ï¯¡¢´äºäÔèÆó (2001)
The Mechanism Related to ST-segment
Reelevation After Primary Coronary Angioplasty.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí
²ñ, µþÅÔ
- ·ª¸¶ÍµÉ§¡¢ÈªÅÄ·û¸ã¡¢ÃæÂ¼À¿»Ö¡¢ßÀÅÄ¿®°ì¡¢ÃݲְìºÈ¡¢Åò»³ÎáÊ塢̣¼ ½ã¡¢
¿ù±ºÅ¯Ï¯¡¢´äºäÔèÆó(2001)
Detection of Stunned Myocardium and its Relation to
Functional Recovery of Left Ventricular Function After Succseeful Primary PTCA.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ, µþÅÔ
- ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢ßÀÅÄ¿®°ì¡¢·ª¸¶ÍµÉ§¡¢ÃݲְìºÈ¡¢ÅÏî´½á»Ò¡¢ÇÏÅÂÀµ
¿Í¡¢¿ù±ºÅ¯Ï¯¡¢´äºäÔèÆó(2001)
Quantitative Estimation of Myocardial Salvage
After Primary Coronary Angioplasty in Patients With Angiographic No Reflow.
Coronary Angioplasty in Patients With Angiographic No Reflow.
¡¡¡¡Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ,¡¡µþÅÔ
- ÃݲְìºÈ¡¢Ruiz¡¡Mirta¡¢Riou¡¡Laurent M¡¢´äºäÔèÆó¡¢Watson¡¡Denny D¡¢
Beller¡¡George A, Glover¡¡David K (2001)
123I-BMIPP uptake is enhanced relative
to perfusion when injected early after reflow in a canine model of reperfused,
viable myocardium.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ, µþÅÔ
- ÃݲְìºÈ¡¢Ruiz¡¡Mirta¡¢Petruzella¡¡Frank D¡¢ÃæÂ¼À¿»Ö¡¢´äºäÔèÆó¡¢Watson¡¡
Denny D¡¢Beller¡¡George A¡¢Glover¡¡David K (2001)
99mTc-sestamibi uptake
accurately predicts myocardial viability in a canine model of partial coronary
reperfusion through a severe residual stenosis.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ,
¡¡¡¡µþÅÔ
- Ê¡°æÀ¯·Ä¡¢ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢ÃݲְìºÈ¡¢ßÀÅÄ¿®°ì¡¢ËåÈø ·ò¡¢´äºäÔè
Æó (2001)
Primary PTCA¾ÉÎã¤Ë¤ª¤±¤ëNicorandil ¤Î¿´¶Ú·ìή²þÁ±¸ú²Ì
Technetium-99m Tetrofosmin ¿´¶ÚSPECT¤òÍѤ¤¤¿¸¡Æ¤.¡¡
Âè49²óÆüËÜ¿´Â¡
ɳزñ³Ø½Ñ½¸²ñ¡¢ ¹Åç
- ȪÅÄ·û¸ã¡¢ÃæÂ¼À¿»Ö¡¢¿ù±ºÅ¯Ï¯¡¢ÃݲְìºÈ¡¢·ª¸¶ÍµÉ§¡¢´äºäÔèÆó (2001)
QGS
¤Î³ÈÄ¥Ëö´üÁü¤ÏºÆÁÂÄÌ¿´¶Ú¤ÎÊɱ¿Æ°¤Î²óÉü¤ò¤è¤êÀµ³Î¤Ëͽ¬¤·¤¦¤ë.
Âè41
²óÆüËÜ³Ë°å³Ø²ñÁí²ñ, ¶âÂô
- ·ª¸¶ÍµÉ§¡¢ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢ÃݲְìºÈ¡¢ßÀÅÄ¿®°ì¡¢Ê¡°æÀ¯·Ä¡¢ÃæÂ¿°Í
»Ò¡¢´äºäÔèÆó(2001)
Primary PTCAľ¸å¤ÎStunned Myocardium¤Î¸¡½Ð-QGS
¤òÍѤ¤¤¿¸¡Æ¤-.
Âè41²óÆüËÜ³Ë°å³Ø²ñÁí²ñ, ¶âÂô
- Ê¡°æÀ¯·Ä¡¢ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢ÃݲְìºÈ¡¢ßÀÅÄ¿®°ì¡¢ËåÈø ·ò¡¢´äºäÔè
Æó (2001)
Primary PTCA¾ÉÎã¤Ë¤ª¤±¤ëNicorandil ¤Î¿´¶Ú·ìή²þÁ±¸ú²Ì
Technetium-99mTetrofosmin ¿´¶ÚSPECT¤òÍѤ¤¤¿¸¡Æ¤.
Âè41²óÆüËܳË
°å³Ø²ñÁí²ñ, ¶âÂô
- µÜºäÍÛ»Ò, ÄÔ µ×»Ò, »³Åĸ÷°ì, ÆÁ±Ê ÃÒ, À¾¾å¾°»Ö, ´äºäÔèÆó (2001)
·ò
¿Ç¤Çǧ¤á¤¿Brugada·¿¿´ÅſޤÎÄÉÀ×Ä´ºº.
Âè98²óÆüËÜÆâ²Ê³Ø²ñÁí²ñ¡¢
²£ÉÍ
- Miyasaka Y, Tsuji H, Yamada K, Tokunaga S, Iwasaka T and Sugiura T (2001)
Prevalence and mortality of the Brugada type electrocardiogram in a general
population.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Tsuji H, Oue K, Yamada K and Iwasaka T (2001)
A randomized study to compare
3mg with 5mg of warfarin as a starting dose for Japanese patients with atrial
fibrillation.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Yamamoto Y, Kamihata H, Tsuji H, Morita Y, Miyoshi H, Yamada K, Hatada K and
Iwasaka T (2001)
The DD genotype of the angiotensin I-converting enzyme is a
major risk factor for diffuse in-stent restenosis.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢
µþÅÔ
- Yamada K, Tsuji H, Tokunaga S and Iwasaka T (2001)
Effect of beta-blockers on
mortality of Japanese patients after acute myocardial infarction in the reperfusion
era.
¡¡Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Nagahama Y, Tsuji H, Kamihata H, Morita Y, Yamamoto Y, Miyoshi H, Hatada
K, Yamada K, Tsuka Y, Kawamura A and Iwasaka T (2001)
Differences in clinical
features and prevalence of coronary artery disease between Japan and USA.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Tsuji H, Yamada K, Kimura Y and Iwasaka T (2001)
Anemia affects plasma brain
natriuretic peptide (BNP) level.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Motohiro M, Kudou Y, Fukui M, Baden M, Sugiura T, Yuasa F and Iwasaka T(2001)
Relation between postexercise systolic blood pressure response and myocardial
ischemia assessed by technetium-99m tetrofosmin.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí
²ñ¡¢µþÅÔ
- ¡¡Yuyama R, Yuasa F, Mimura J, Kawamura A and Iwasaka T(2001)
Angiotensin II
receptor antagonist improves endothelium mediated vasodilation in patients with
chronic heart failure.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Mimura J, Yuasa F, Yuyama R, Kawamura A and Iwasaka T(2001)
The role of
cardiac and peripheral sympathetic function on exercise capacity in patients with
left ventricular dysfunction.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Mimura J, Yuasa F, Yuyama R, Kawamura A and Iwasaka T(2001)
Sympathetic
effect of peripheral chemoreflex activation at rest and during exercise in mild
heart failure.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Kawamura A, Yuasa F, Yuyama R, Mimura J and Iwasaka T(2001)
The effect of
alpa-adrenergic agonist on baroreflex control of heart rate and sympathetic nerve
activity in patients with left ventricular dysfunction.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñ
Áí²ñ¡¢µþÅÔ
- ¡¡Åò»³ÎáÊå¡¢ÅòÀõʸͺ¡¢Ì£Â¼ ½ã¡¢´äºê¿¿²Â¡¢²Ï¼¹¸¹°¡¢´äºäÔèÆó(2001)
¥·¥ó¥Ý¥¸¥¦¥à¡ÚÎ×¾²³Æ²ÊÎΰè¤Ë¤ª¤±¤ë±¿Æ°À¸Íý¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¡Û
µÞÀ¿´¶Ú¹¼ºÉ¾É²óÉü´ü¤Ë¤ª¤±¤ëû´ü±¿Æ°ÎÅË¡¤¬¼«Î§¿À·Ð¤ËÍ¿¤¨¤ë±Æ¶Á
Âè38²óÆüËÜÎ×¾²À¸Íý³Ø²ñÁí²ñ, ½©ÅÄ
- ¡¡´äºê¿¿²Â¡¢ÅòÀõʸͺ¡¢Åò»³ÎáÊ塢̣¼ ½ã¡¢²Ï¼¹¸¹°¡¢´äºäÔèÆó(2001)
¿´ÉÔÁ´¤Ë¤ª¤±¤ë·ì´ÉÆâÈ鵡ǽ¤È¸ò´¶¿À·Ð¤ÎÁê¸ßºîÍÑ.
Âè38²óÆüËÜÎ×¾²À¸Íý³Ø²ñÁí²ñ, ½©ÅÄ
- ¡¡²Ï¼¹¸¹°¡¢ÅòÀõʸͺ¡¢Åò»³ÎáÊ塢̣¼ ½ã¡¢´äºê¿¿²Â¡¢´äºäÔèÆó(2001)
ËýÀ¿´ÉÔÁ´¤Ë¤ª¤±¤ë¿´ÇÙ°µ¼õÍÆÂÎÈ¿¼Íµ¡Ç½¤È¿À·Ð±ÕÀ°ø»Ò¤Î¸¡Æ¤.
Âè38²óÆüËÜÎ×¾²À¸Íý³Ø²ñÁí²ñ, ½©ÅÄ
- ²Ï¼¹¸¹°¡¢ÅòÀõʸͺ¡¢Åò»³ÎáÊ塢̣¼ ½ã¡¢´äºê¿¿²Â¡¢´äºäÔèÆó(2001)
ËýÀ¿´ÉÔÁ´Îã¤Ë¤ª¤±¤ë¿´ÇÙ°µ¼õÍÆÂÎÈ¿¼Íµ¡Ç½¤È¿À·Ð±ÕÀ°ø»Ò¤Î´Ø·¸.
Âè49²óÆüËÜ¿´Â¡É³زñÁí²ñ¡¢¹Åç
- ÀÆÆ£Âç¼ù¡¢ÅòÀõʸͺ¡¢¿ÀÈ«¹¨¡¢¹â»³¹¯Éס¢´äºäÔèÆó(2001)
µÞÀ¿´¶Ú
¹¼ºÉ¾É¤Ë¤ª¤±¤ëChest Pain Center¤ÎÍÍÑÀ.Âè49²óÆüËÜ¿´Â¡É³زñÁí²ñ¡¢
¹Åç
- ¹©Æ£½ç¹°¡¢¸µ¹¾Ç·¡¢ºäËÜ·ûɧ¡¢Ê¡°æÀ¯·Ä¡¢ÅòÀõʸͺ¡¢ÇÏÅÂÀµ¿Í¡¢¿ù±º
ůϯ¡¢´äºäÔèÆó(2001)
Exercise hypertension(Ex-HT)¤È´§Æ°Ì®¼À´µ(CAD)¤Î
´Ø·¸¤Ë¤Ä¤¤¤Æ.
Âè98²óÆüËÜÆâ²Ê³Ø²ñÁí²ñ¡¢²£ÉÍ
- À¾¾å¾°»Ö¡¢´äºäÔèÆó¡Ê2001¡Ë
µõ·ìÀ¿´¼À´µ¤Ëȼ¤¦ÉÔÀ°Ì®¤ò½¤¾þ¤¹¤ë°ø»Ò
¡Ê¥Ñ ¥Í¥ë¥Ç¥£¥¹¥«¥Ã¥·¥ç¥ó¡Ë.
Âè28²óÆüËܽ¸Ãæ¼£ÎųزñÁí²ñ¡¢Åìµþ
- Hamada H, Nishiue T, Nakamura S and Iwasaka T (2001)
Relation between
transmural trends of myocardial integrated backscatter and infarct expansion
in-patients with acute Q wave anterior myocardial infarction.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Nishiue T, Kamihata H, Matsubara H, Tsutsumi Y, Fujiyama S and Iwasaka
T(2001)
Evaluation of Therapeutic Angiogenesis Using Myocardial Contrast
Echocardiography.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Hamada H, Nishiue T, Nakamura S, Kamihata H and Iwasaka T(2001)
TIMI
Frame Count Immediately After Successful Primary Coronary Angioplasty
as a Predictor of Functional Recovery in Patients With Acute Myocardial
Infarction.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Matsumoto N, Nishiue T, Kimura Y, Takayama Y, Imuro Y and Iwasaka T (2001)
The Greater Amount of Sub-pericardial Fat is Associated With Left Ventricular
Diastolic Dysfunction in Obese Subjects.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- »þ²¬¿¿Íý¡¢À¾¾å¾°»Ö¡¢ÃæÂ¼À¿»Ö¡¢ÈªÅÄ·û¸ã¡¢´äºäÔèÆó(2001)
¿´¶Ú¹¼ºÉ¤Ë¤ª
¤±¤ëPower Doppler¿´¶Ú¥³¥ó¥È¥é¥¹¥È¥¨¥³¡¼¤ÈTc-99m-tetrofosmin¿´
ÅÅ¿ÞÆ±´üÄêÎÌŪ¿´¶Ú¥·¥ó¥Á¤Ë¤è¤ë¿´¶Ú·ìή¤ÎÈæ³Ó.
Âè49²óÆüËÜ¿´Â¡É³Ø
²ñÁí²ñ¡¢¹Åç
- ÄÔ µ×»Ò¡¢°æ¾å Ű¡¢±àÆ£ÍÛ»Ò¡¢ËÌÀî¹á¿¥¡¢ÌÚ¸¶ ͵ (2001)
Î×¾²±Ö³Ø¤òÂêºà¤È¤·¤¿¼ÂÁ©Åª¤Ê°å³ØÅý·×½èÍý±é½¬¤Î»î¤ß¤È¤½¤Îɾ²Á.
Ê¿À®
13ǯÅÙ¾ðÊó½èÍý¶µ°é¸¦µæ½¸²ñ¡¢Ï²λ³
- Miyoshi H, Kamihata H, Kawamura T, Tsuka Y, Hatada K, Yamada K,
Yamamoto Y, Nagahama Y, Morita Y and Iwasaka T (2001)
Glycemic
Control and In-Stent Restenosis in Patients with Diabetes Mellitus.
Âè65ÆüËܽ۴ĴïɳزñÁí²ñ¡¢µþÅÔ
- Hara H, Morita Y, Kamihata H, Hirowatari Y, Iwasaka T and Takahashi H (2001)
Usefulness of measurement of plasma and whole blood serotonin levels
in patients with ischemic heart diseases.
Âè65ÆüËܽ۴ĴïɳزñÁí²ñ¡¢µþÅÔ
- Yamada K,Tsuka H,Tokunaga T, Watanabe J, Miyasaka Y and Iwasaka T
(2001)
Effect of Beta-blockers on Mortality of Japanese Patients after
Acute Myocardial Infarction in the Reperfusion Era.
Âè65ÆüËܽ۴Ĵï
ɳزñÁí²ñ¡¢µþÅÔ
- ȪÅÄ·û¸ã¡¢ÄÍ¡¡Ë§ÌÀ¡¢»³ËÜů»Ë¡¢²Ï¼¹¸¹°¡¢´äºäÔèÆó (2001)
small vessel
¤ËÂФ¹¤ëstentαÃÖ¤ÎÍÍÑÀ.
Âè1²ó ÆüËÜ¿´·ì´É¥«¥Æ¡¼¥Æ¥ë¼£Îųزñ ¡¢
¾®ÁÒ
- »°¹¥¹Åµ¡¢¿ÀÈ«¡¡¹¨¡¢¿ÝëÊÝÉס¢±ÊßÀ¡¡Íס¢»³Åĸ÷°ì¡¢ÈªÅÄ·û¸ã¡¢ÄÍ¡¡Ë§¡¡
¡¡¡¡ÌÀ¡¢»³ËÜů»Ë¡¢²Ï¼¹¸¹°¡¢´äºäÔèÆó (2001)
ÅüǢɴµ¼Ô¤Ë¤ª¤¤¤Æ¥¤¥ó
¡¡¡¡¥¿¡¼¥Ù¥ó¥·¥ç¥ó»þ¤Î·ìÅü¥³¥ó¥È¥í¡¼¥ë¤Ï¥¹¥Æ¥ó¥ÈºÆ¶¹ºõ¤ò¸º¾¯¤µ¤»¤ë¤«¡©
¡¡
¡¡¡¡Âè1²ó ÆüËÜ¿´·ì´É¥«¥Æ¡¼¥Æ¥ë¼£Îųزñ¡¢ ¾®ÁÒ
- »°¹¥¹Åµ¡¢¿ÀÈ«¡¡¹¨¡¢¿ÝëÊÝÉס¢±ÊßÀ¡¡Íס¢»³Åĸ÷°ì¡¢ÈªÅÄ·û¸ã¡¢ÄÍ¡¡Ë§¡¡
¡¡¡¡ÌÀ¡¢»³ËÜů»Ë¡¢²Ï¼¹¸¹°¡¢´äºäÔèÆó (2001)
ÅüǢɴµ¼Ô¤Ë¤ª¤¤¤Æ¥¤¥ó¥¿¡¼¡¡
¡¡¡¡¥Ù¥ó¥·¥ç¥ó»þ¤Î·ìÅü¥³¥ó¥È¥í¡¼¥ë¤Ï¥¹¥Æ¥ó¥ÈºÆ¶¹ºõ¤ò¸º¾¯¤µ¤»¤ë¤«¡©
¡¡¡¡Âè49²óÆüËÜ¿´Â¡É³زñ³Ø½Ñ½¸²ñ¡¢¹Åç
- Tsuka Y, Nagahama Y, Kamihata H, Morita Y, Yamamoto Y, Miyoshi
H, Hatada K, Yamada K, Kawamura A and Iwasaka T¡¡(2001)
Cutting
Balloon Angioplasty Before Stenting has a Benefit for In-stent Restenosis.
Âè65²óÆüËܽ۴ĴïɳزñÁí²ñ µþÅÔ
- ÄÍ¡¡Ë§ÌÀ¡¢¿ù±ºÅ¯Ï¯¡¢ÈªÅÄ·û¸ã¡¢±ÊßÀ¡¡Íס¢´äºäÔèÆó (2001)
µÞÀ²¼Êɹ¼
¡¡¡¡ºÉ ¤Ë¤ª¤±¤ëÁ°¶»ÉôͶƳ¡ÊV1¡¢V2¡ËST¾å¾º¤ÎÎ×¾²Åª°ÕµÁ¡¥
¡¡ Âè28²óÆüËܽ¸Ãæ¼£ÎŰ峨²ñ ¡¢Åìµþ
- ÄÍ¡¡Ë§ÌÀ¡¡¿¹ÅÄ¡¡´²¡¢¿ÀÈ«¡¡¹¨¡¢¿ÝëÊÝÉס¢±ÊßÀ¡¡Íס¢»°¹¥¹Åµ¡¢»³Åĸ÷¡¡
°ì¡¢ ȪÅÄ·û¸ã¡¢»³ËÜů»Ë¡¢²Ï¼¹¸¹°¡¢µþ°æ»Ö¿¥¡¢´Ó°æÌ¤Æà»Ò¡¢¸¶¡¡¹î»Ò¡¢¡¡
¹â¶¶ÇìÉס¢´äºäÔèÆó (2001)
¥¹¥Æ¥ó¥ÈÆâºÆ¶¹ºõ¤È±ê¾É¤È¤Î´ØÏ¢¡¥
Âè1²óÆüËÜ¿´·ì´É¥«¥Æ¡¼¥Æ¥ë¼£Îųزñ¡¢ ¾®ÁÒ
- ÄÍ¡¡Ë§ÌÀ¡¢±ÊßÀ¡¡Íס¢¿ÀÈ«¡¡¹¨¡¢¿ÝëÊÝÉס¢»°¹¥¹Åµ¡¢»³Åĸ÷°ì¡¢ÈªÅÄ·û
¸ã¡¢»³ËÜů»Ë¡¢²Ï¼¹¸¹°¡¢µþ°æ»Ö¿¥¡¢´Ó°æÌ¤Æà»Ò¡¢¸¶¡¡¹î»Ò¡¢¹â¶¶ÇìÉס¢
´äºäÔèÆó (2001)
´§Ú»½Ì¤È±ê¾É¤È¤Î´ØÏ¢¡¥
Âè1²ó¡¡ÆüËÜ¿´·ì´É¥«¥Æ¡¼¥Æ
¥ë¼£Îųزñ¡¢ ¾®ÁÒ
- ÄÍ¡¡Ë§ÌÀ¡¢±ÊßÀ¡¡Íס¢¿ÀÈ«¡¡¹¨¡¢¿ÝëÊÝÉס¢»°¹¥¹Åµ¡¢»³Åĸ÷°ì¡¢ÈªÅÄ·û
¸ã¡¢»³ËÜů»Ë¡¢²Ï¼¹¸¹°¡¢µþ°æ»Ö¿¥¡¢´Ó°æÌ¤Æà»Ò¡¢´äºäÔèÆó (2001)
Cutting
Balloon¤Ë¤è¤ëStentÁ°³ÈÄ¥¤Î͸úÀ¡¥
Âè1²ó¡¡ÆüËÜ¿´·ì´É¥«¥Æ¡¼¥Æ¥ë
¼£Îųزñ¡¢ ¾®ÁÒ
- Kamihata H, Matsubara H, Nishiue T, Tsutusmi Y, Fujiyama S, Masaki H and
Iwasaka T(2001)
Therapeutic angiogenesis of ischemic myocardium using
autologous bone marrow cell implantation that side-supplies of angioblasts,
angiogenic ligands and cytokines.
Âè65²ó ÆüËܽ۴ĴïɳزñÁí²ñ¡¢µþÅÔ
- Kamihata H, Iwasaka T, Fujiyama S, Tsutusmi Y, Nishiue T and Matsubara H
(2001)
Implantation of Autologous Bone Marrow Cells into Ischemic Myocardium
Enhances Collateral Perfusion and Regional Function via Sude-supply of
Angioblasts and Angiogenic Ligands (VEGF ,bFGF,Angiopoietin-1).
Âè65²ó ÆüËܽ۴ĴïɳزñÁí²ñ¡¢µþÅÔ
- Æâ»³ÍÕ»Ò¡¢¾¾¸¶¹°ÌÀ¡¢¿¹¡¡ÂÙÀ¶¡¢¼ÆºêÂٱ䡢ǽÀªÆØ»Ò¡¢ÇßÅŬµ×¡¢±ÊÅÄ ÅÐ
»Ö»Ò¡¢´äºäÔèÆó¡Ê2001¡Ë
TGF-¦Â¤Ë¤è¤ëFibronectin°äÅÁ»Òȯ¸½¤Ï¾åÈéÀ®Ä¹
°ø»Ò¼õÍÆÂΤζ¦Ìò³èÀ²½¤ò²ð¤·¤ÆÄ´Àᤵ¤ì¤ë.
Âè44²óÆüËܿա³Ø²ñ³Ø½Ñ
Áí²ñ¡¢Åìµþ
- ǽÀªÆØ»Ò¡¢¿¹¡¡ÂÙÀ¶¡¢¾¾¸¶¹°ÌÀ¡¢Æâ»³ÍÕ»Ò¡¢¾®ºêÆÆ»Ö¡¢ÀµÌÚ¹ÀºÈ¡¢¼Æºê
Âٱ䡢ÇßÅŬµ×¡¢±ÊÅÄÅлֻҡ¢´äºäÔèÆó¡Ê2001¡Ë
¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥óII¤Ï
HB¡ÝEGFʬÈç¤ò²ð¤·¤Æ¾åÈéÀ®Ä¹°ø»Ò¼õÍÆÂΤò¶¦Ìò ³èÀ²½¤µ¤»glucose
transporter¡ÊGlut1¡Ë°äÅÁ»Òȯ¸½¤òж¿Ê¤¹¤ë.
Âè44²óÆüËܿա³Ø²ñ³Ø½ÑÁí²ñ¡¢
Åìµþ
- ¿¹¡¡ÂÙÀ¶¡¢Æâ»³ÍÕ»Ò¡¢Ç½ÀªÆØ»Ò¡¢´ßËÜŵ»Ò¡¢ÀµÌÚ¹ÀºÈ¡¢±ÊÅÄÅлֻҡ¢ÇßÅÄ
¹¬µ×¡¢¾¾¸¶¹°ÌÀ¡¢´äºäÔèÆó¡Ê2001¡Ë
¥Ñ¥ë¥Ü¥¦¥£¥ë¥¹´¶À÷¾É¤Ë¤è¤ëµÞÀ»å
µåÂοձê¤Î°ìÎã.
Âè31²óÆüËܿա³Ø²ñÀ¾Éô³Ø½ÑÂç²ñ¡¢¶âÂô
- ¿¹¡¡ÂÙÀ¶¡Ê2001¡Ë
¿Õ¼À´µ¤Î±ÉÍÜ¡¦¿©»ö´ÉÍý¡Ê´ðÄ´¹Ö±é¡Ë.
Âè48²óÆüËܱÉÍܲþÁ±³Ø²ñ³Ø½ÑÁí²ñ¡¢Âçºå
- ¾®ºêÆÆ»Ö¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢¾åÅÄ²ÃÆà»Ò¡¢µ×ÊÝÅÄâÃͳÈþ¡¢¡¡
¡¡¡¡´äºäÔè¥Ë¡Ê2001¡Ë
¡¡ÅüǢɿÇÎŤˤª¤±¤ëÃϰ豿ư»ØÆ³»Î¤È¤Î¥Á¡¼¥à¥×¥ì¥¤
¡¡¡¡? µþºå¥á¥Ç¥£¥«¥ë¥Õ¥£¥Ã¥È¥Í¥¹¥Í¥Ã¥È¥ï¡¼¥¯¤ÎÀßΩ-
¡¡Âè38²óÆüËÜÅüÇ¢ÉÂ
³Ø²ñ¶áµ¦ÃÏÊý²ñ¥·¥ó¥Ý¥¸¥¦¥à¡¢Âçºå
- ¾®ºêÆÆ»Ö¡¢ÌÚ¼¡¡¾÷¡¢´äºäÔè¥Ë(2001)
ÀìÌç°åÎŵ¡´Ø¤ÈÊ£¿ô¤Î±¿Æ°»ÜÀß
¡¡¡¡¤È¤ÎÏ¢·È ?À¸³è½¬´·É´µ¼Ô¤Ø¤Î±¿Æ°ÎÅË¡»Ù±ç¥·¥¹¥Æ¥à¤Î¹½ÃÛ-
¡¡¡¡Âè15²óÎ×¾²±¿Æ°ÎÅË¡¸¦µæ²ñ¥·¥ó¥Ý¥¸¥¦¥à¡¢Âçºå
- ĹëÀîδÀµ¡¢¾®ºêÆÆ»Ö¡¢¾¾¸¶¹°ÌÀ¡¢¿¹ ÂÙÀ¶¡¢ÀµÌÚ¹ÀºÈ¡¢ÌÚ¼¡¡¾÷¡¢²³À
¡¡¡¡¸÷ɧ¡¢À¸¿å ¹¸¡¢À¾Àî¸÷½Å¡¢´äºäÔè¥Ë¡¡(2001)
S100ÃÁÇò¤Îȯ¸½Ä´Àá°ø»Ò¡¡
¡¡¡¡¤Ë´Ø¤¹¤ë¸¡Æ¤.¡¡
Âè44²óÆüËÜÅüǢɳزñÁí²ñ¡¢µþÅÔ
- Maeda A, Toyoda N, Imai Y, Nishikawa M and Iwasaka T (2001)
Expression and
regulation of type 2 iodothyronine deiodinase in human artery smooth
muscle cells.
Âè65²óÆüËܽ۴ĴïɳزñÁí²ñ¡¢µþÅÔ
- ËÅÄŶ½¡¢Á°ÅÄ¾Ï²í¡¢º£°æÍµ»Ò¡¢À¾Àî¸÷½Å¡¢´äºäÔèÆó (2001)
¥Ò¥È·ì´ÉÊ¿
³ê¶ÚºÙ˦¤Ëȯ¸½¤¹¤ë¹Ã¾õÁ£¥Û¥ë¥â¥óÂå¼Õ¹ÚÁǤÎȯ¸½Ä´Àᵡ½ø.
Âè98²óÆü
ËÜÆâ²Ê³Ø²ñÁí²ñ¡¢²£ÉÍ
- Okigaki M, Matsubara H and Iwasaka T (2001)
Multiple Functional Role of PYK2 in
Macrophage Migration revealed by PYK2 knock-out mice.
Âè65²ó ÆüËܽ۴Ĵï
ɳزñÁí²ñ¡¢µþÅÔ
- Okigaki M, Matsubara H and Iwasaka T (2001)
Multiple Functional Role of PYK2 in
Cytokine Induction from Macrophage revealed by PYK2 knock out mice.
Âè65²ó ÆüËܽ۴ĴïɳزñÁí²ñ¡¢µþÅÔ
- Matsubara H(2001)
First Report of Clinical Trial of Autologous Implantation
of Bone Marrow Cells to Patients with Arteriosclerosis Obliterans-Molecular
Mechanism for Marrow Cells-Induced Angiogenesis.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñ
Áí²ñ¡¢µþÅÔ
- Matsubara H, Masaki H, Tateishi E, Iwsaka T (2001)
First Report of Clinical Trial
of Autologous Implantation of Bone Marrow Cells of Patients with Arterioscle
rosis Obliterans-Molecular Mechanism for Marrow Cells-Induced Angiogenesis.
¡¡ Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Uchiyama Y, Matsubara H, Mori Y, Kosaki A, Tsutsumi Y, Shibasaki Y, Fujiyama
S, Nose A, Iba o, Hasagawa T, Tateishi E and Iwasaka T (2001)
Comparative study of
ACE Inhibitor and angiotensin2 type1 receptor antagpnist on regression of caro
tid-artery IMT In hypertensives.
¡¡Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Matsubara H, Murasawa S, Mori Y, Shibasaki Y, Masaki H, Maruyama K,
TsutsumiY, Fujiyama S, Iba O, Tateishi E and Iwasaka T (2001)
Evidence
That Intrinsic Kinase Domain of EGF Receptor Is not Involved In Angiotensin 2
mediated Transactiv ation of EGF receptor.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Tsutsumi Y, Matsubara H, Mori Y, Murasawa S, Maruyama K, Shibasaki Y,
Uchiyama Y, Fujiyama S, Nose A and Iwasaka T (2001)
Angiotensin type2(AT2) ¡¡
¡¡ receptor Inhibits AT1-mediated Intracellular alkalosis to enhance kinin
ssproduction In vasucular smooth muscle cell from vascular-targeted
AT2-transgenic mice.¡¡
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Tateishi E, Masaki H, Matsubara H, Mori Y, Shibasaki Y, Tsutsumi Y, Fujiyama
S, Iba O and Iwakasa T (2001)
Clinically Feasible Theraputic Angiogenesis using Autol
ogous Implantation of Bone Marrow-derived Mononuclear Cells to Ischemic limbs.¡¡
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Shibasaki Y, Matsubara H, Mori Y, Masaki H, Kosaki A, Tsutsumi Y, Uchiyama Y,
Fujiyama S, Nose A, Iba O, Tateishi E and Iwasaka T (2001)
Angiotensin 2 Receptor
Inhibits EGF Receptor Transactivation by Increasing Association of SHP-1 Tyro
sine Phosphatase to Inactivate Mitogen-activating Protein Family Kinases.¡¡
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Murasawa S, Matsubara H, Mori Y, Masaki H, Tsutsumi Y, Shibasaki Y, Fujiyama
S, Iba O, Tateishi E and Iwasaka T (2001)
Angiotensin II Initiates Tyrosine Kinase Py
k2-Dependent Signalings Leading to Activation to Rac1-Mediated c-Jun NH2-Ter
minal Kinase.
¡¡Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- Maruyama K, Matsubara H, Mori Y, Shibasaki Y, Masaki H, Tsutsumi Y, Fujiyama
S, Iba O, Tateishi E and Iwasaka T (2001)
Angiotensin AT1 and AT2 Receptors
Differen tially Regulate the Expression of Tissue Factor In Cardiac microvascular
End othelial Cells.¡¡
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- ¼ÆºêÂٱ䡢ÀµÌÚ¹ÀºÈ¡¢À¾¾å¾°»Ö¡¢¾¾¸¶¹°ÌÀ¡¢¹â¶¶ÇìÉס¢´äºäÔèÆó(2001)
¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥óII1·¿¼õÍÆÂÎÙɹ³Ìô¤ÎÆ©ÀÏ´µ¼Ô¤Ë¤ª¤±¤ë¿´¶ÚÈîÂ硦Á¡°Ý
²½ÍÞÀ©¸ú²Ì¤Ë¤Ä¤¤¤Æ¸¡Æ¤-ACEÁ˳²ÌôµÚ¤ÓCaÙɹ³Ìô¤È¤ÎÈæ³Ó¸¡Æ¤-
Âè24²óÆüËܹâ·ì°µ³Ø²ñÁí²ñ¡¢Âçºå
- Åä¡¡µÁÌÀ¡¢¾¾¸¶¹°ÌÀ¡¢¿¹¡¡ÂÙÀ¶¡¢ÀµÌÚ¹ÀºÈ¡¢Æ£»³Áí°ìϺ¡¢°æÄí¡¡Íý¡¢¼Æºê
Âٱ䡢´Éë¡¡·ò¡¢ËÙÆâÀµ»Ì¡¢Ìîß·Îɵס¢¹â¶¶ÇìÉס¢´äºäÔèÆó(2001)
¡¡
¡¡ ¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥óII¤È·ì´ÉºÆÀ¸¥à°äÅÁ»ÒÁàºîưʪ¤òÍѤ¤¤ÆÌÀ¤é¤«¤Ë¤Ê¤Ã¤¿
¼õÍÆÂÎ¥µ¥Ö¥¿¥¤¥×°Í¸À¤Îµõ·ìÉô·ì´É¿·À¸ºîÍÑ.¡¡
Â裲£´²óÆüËܹâ·ì°µ³Ø²ñ
Áí²ñ¡¢Âçºå
¡¡
- ½©ÅÄͺ»°¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢´äºäÔèÆó(2001)
Enhanced ventilatory
response during exercise might play important role in sleep apnea of
patients with heart failure.
Âè65²óÆüËÜ½Û´Ä´ï³Ø²ñÁí²ñ¡¢µþÅÔ
- ÌÚ¼¡¡¾÷¡¢»³ËÜů»Ë¡¢¾®¾¾¡¡¹á¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó¡Ê2001¡Ë
·ì¾®ÈÄͳ¡¡
¡¡ Íè¥Þ¥¤¥¯¥í¥Ñ¡¼¥Æ¥£¥¯¥ë¡¢·ì¾®ÈijèÀʪ¼Á¤Ë¤è¤ë¹â·ì°µ±¿Æ°¸ú²Ì ¤Î¸¡Æ¤.
¡¡ Âè49²óÆüËÜ¿´Â¡É³زñ¡¢¹Åç
- ¾®¾¾¡¡¹á¡¢ÌÚ¼¡¡¾÷¡¢»³ËÜů»Ë¡¢Ä¹Ã«Àî¡¡¸¼¡¢¾¾ËÜŵ»Ò¡¢´äºäÔèÆó(2001)
¹â·ì°µ´µ¼Ô¤ÎÍ»ÀÁDZ¿Æ°¤Ë¤ª¤±¤ë»ý³ÀCaÙɹ³ºÞ¤Î¼«Î§¿À·ÐÈ¿±þ
¡¡ ¤ËµÚ¤Ü¤¹±Æ¶Á.
Âè49²óÆüËÜ¿´Â¡É³زñ¡¢¹Åç
- »³ËÜů»Ë¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
¶áÀÖ³°Àþʬ
¸÷Ë¡¤Ë¤è¤ë±¿Æ°»þËö¾¿»ÀÁÇÆ°ÂÖ¤Îɾ²Á.
Âè49²óÆüËÜ¿´Â¡É³زñ¡¢¹Åç
- ÂçË̺»Í³Íø¡¢±º¸ýŵ»Ò¡¢ÍêÅÄÍ¥»Ò¡¢Ê¿¸¶¥ß¥«¡¢±ÊÅÄ¿¿Í³Èþ¡¢¿ùËÜ·É»Ò
(2001)
¿´¶Ú¹¼ºÉÆþ±¡»þ¶µ°é¸ú²Ì¤Î±ó³ÖÀ®ÀÓ.
Âè49²óÆüËÜ¿´Â¡É³زñ¡¢
¹Åç
- ¾®¾¾¡¡¹á¡¢ÌÚ¼¡¡¾÷¡¢»³ËÜů»Ë¡¢Ä¹Ã«À¡¢¾¾ËÜŵ»Ò¡¢´äºäÔèÆó(2001)
¹â·ì°µ´µ¼Ô¤Î»ý³ŪͻÀÁDZ¿Æ°»þ¤Î·ì°µ¡¢¿´Çï¿ô¤Ë¤ª¤è¤Ü¤¹¼«Î§¿À·Ð
µ¡Ç½.
Âè40²óÆüËܹâ·ì°µ³Ø²ñÁí²ñ¡¢Âçºå
- »³ËÜů»Ë¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
̵»ÀÁDZ¿Æ°ïçÃͤȻÀÁǸúΨ¤È¤Î´Ø·¸.
Âè56²óÆüËÜÂÎÎÏ°å³Ø²ñ¡¢ÀçÂæ
- ¾åÅÄ²ÃÆà»Ò¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
¥¢¥¯¥Æ¥£¥Ö¥È¥ì¡¼¥µ¡¼¤Ë¤è¤ë±¿Æ°ÎÅË¡¸ú²Ì¤Î¸¡Æ¤.
Âè56²óÆüËÜÂÎ
ÎÏ°å³Ø²ñ¡¢ÀçÂæ
- µ×ÊÝÅÄ¿¿Í³Èþ¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
¥¹¥È¥ì¥ó¥°¥¹¥¨¥ë¥´¤Ë¤è¤ë²¼»è¶ÚÎϤε¡Ç½ÅªÉ¾²Á.
Âè56²óÆüËÜÂÎ
ÎÏ°å³Ø²ñ¡¢ÀçÂæ
- ¾®¾¾¡¡¹á¡¢ÌÚ¼¡¡¾÷¡¢»³ËÜů»Ë¡¢Ä¹Ã«Àî¡¡¸¼¡¢¾¾ËÜŵ»Ò¡¢´äºäÔèÆó
¡¡¡¡(2001)
¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¤ËµÚ¤Ü¤¹¦Â£³¥¢¥É¥ì¥Ê¥ê¥ó¼õÍÆÂΰä
ÅÁ»Ò¿·¿¤Î¸¡Æ¤.
Âè7²óÆüËÜ¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó³Ø²ñ¡¢µ×Î±ÊÆ
- ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
·ì¾®ÈÄͳÍè¥Þ¥¤¥¯¥í¥Ñ¡¼¥Æ¥£¥¯¥ë¡¢·ì¾®ÈijèÀʪ¼Á¤Ë¤ª¤è¤Ü¤¹¿´Â¡
¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¸ú²Ì.
Âè7²óÆüËÜ¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó³Ø²ñ¡¢
µ×Î±ÊÆ
- Æ£ËÜÈ˻ҡ¢±ÊÅÄ¿¿Í³Èþ¡¢±º¸ýŵ»Ò¡¢»ù¶Ì·Ë»Ò¡¢¾åÅÄ²ÃÆà»Ò¡¢µ×ÊÝÅÄâÃͳÈþ¡¢
¿ùËÜ¡¡·É»Ò(2001)
¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó·Ñ³Îã¤Ë¤ª¤±¤ë·Ñ³·¿¡¦¸Ä¿Í
»ØÆ³ÍÑÀ¸³è½¬´·¥Á¥§¥Ã¥¯¥·¥¹¥Æ¥à¤Î³«È¯.
Âè7²óÆüËÜ¿´Â¡¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·
¥ç¥ó³Ø²ñ¡¢µ×Î±ÊÆ
- ÇϾìÅ·¿®¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
ÈîËþ¼£ÎŤˤª¤±¤ë¿´Íý³ØÅª²ðÆþ¤Ë¤Ä¤¤¤Æ¡¼¿´ÍýŪɾ²Á¤Ë´ð¤Å¤¯¿´Íý¥«¥¦¥ó
¥»¥ê¥ó¥°¡¼.
Âè10²óÆüËÜ¿´ÎÅÆâ²Ê³Ø²ñ¡¢ÀçÂæ
- µ×ÊÝμ»Ò¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
ÈîËþ¶µ¼¼¤Î¿©¹ÔưÊѲ½¤ÎÂÎÁÈÀ®¡¢·ìÀ¶»é¼Á¤ËµÚ¤Ü¤¹±Æ¶Á.
Âè39²óÆüËܱÉÍܲþÁ±³Ø²ñ¡¢Âçºå
- ÍÀîâûҡ¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó
(2001)
¼«¸Ê¿½¹ð¥¤¥á¡¼¥¸Ë¡¤Ë¤è¤ë±ÉÍÜÁÇ¡¢¿©ÉÊÊ̱ÉÍÜɾ²Á¤ÎÂÅÅöÀ¤Ë
¤Ä¤¤¤Æ.
Âè39²óÆüËܱÉÍܲþÁ±³Ø²ñ¡¢Âçºå
- ÅÄÅ躴Ï»ҡ¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó
(2001)
ÈîËþ¿©¹Ôư¤È¸ºÎ̸ú²Ì¤Î¸¡Æ¤.
Âè39²óÆüËܱÉÍܲþÁ±³Ø²ñ¡¢Âçºå
- ÇϾìÅ·¿®¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó
(2001)
ÈîËþ±¿Æ°ÎÅË¡»Ü¹ÔÎã¤Ë¤ª¤±¤ë¿´ÍýŪɾ²Á¡¿¥«¥¦¥ó¥»¥ê¥ó¥°¤ÎÍÍÑ
À¡Ý̵ºî°Ù³äÉդˤè¤ë¸¡Æ¤¡Ý.
Âè22²óÆüËÜÈîËþ³Ø²ñ¡¢·²ÇÏ
- ÅÄÅ躴Ï»ҡ¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó
(2001)
¿©»ö¡¦±¿Æ°ÎÅË¡»Ü¹Ô»þ¤Î¶É½êÂλéËÃʬÉۤηлþŪÊѲ½
¡Ý¶áÀÖ³°Ê¬¸÷Ë¡¤Ë¤è¤ëɾ²Á¡Ý.
Âè22²óÆüËÜÈîËþ³Ø²ñ¡¢·²ÇÏ
- ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢»³ËÜů»Ë¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
ADR¤Ë¤è¤ë¹â·ì°µ±¿Æ°ÎÅË¡¤Î¹ß°µ¸ú²Ì¤Î¸¡Æ¤.
Âè12²óÎ×¾²¥¹¥Ý¡¼¥Ä°å³Ø²ñ¡¢Åìµþ
- »³ËÜů»Ë¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
¹âÎð¼Ô±¿Æ°ÎÅË¡¤Ë¤ª¤±¤ë¥¹¥Æ¥Ã¥×¥¨¥¯¥µ¥µ¥¤¥º¤Î¸¡Æ¤.
Âè36²óÆüËÜÎ×¾²À¸Íý³Ø²ñÁí²ñ¡¢½©ÅÄ
- »³ËÜů»Ë¡¢ÌÚ¼¡¡¾÷¡¢¾®¾¾¡¡¹á¡¢µï¸¶ÅÄÁ±»Ê¡¢´äºäÔèÆó(2001)
¶áÀÖ³°Àþʬ¸÷Ë¡¤Ë¤è¤ë»ÀÁǸúΨ.
Âè29²óÆüËÜÌ®´É³Ø²ñÁí²ñ¡¢Âçºå
- Nakamura S, Hatada, K, Kurihara H, Takehana K, Suga Y and Iwasaka. T (2001)
Quantitative-gated SPECT Imaging in the Detection of Stunned Myocardium and
its Relation to Functional Recovery of Left Ventricular Function After Successful
Primary Coronary Angioplasty.
48th Annual Meeting of Seminar of Nuclear
Medicine, Tronto, Canada.
- Nakamura S, Hatada K, Kurihara H, Takehana K, Suga Y and Iwasaka.T (2001)
Detection of Stunned Myocardium Determinating Recovery of Wall Motion in the
Reperfused Area by Quantitative-gated SPECT at Early After Reperfusion.
48th
Annual Meeting of Seminar of Nuclear Medicine, Tronto, Canada.
- Hatada K, Nakamura S, Sugiura T, Kamihata H, Takehana K, Suga Y, Yuyama R,
Mimura J, Hamada S, Kurihara H and Iwasaka T (2001)
Quantitative-ECG gated
Myocardial perfusion Imaging at End-diastole Accurately Estimates Myocardial
Viability After Primary PTCA in Patients With Myocardial Infarction.
48th Annual
Meeting of Seminar of Nuclear Medicine, Tronto, Canada.
- Fukui M, Baden M, Kurihara H, Iwasaka T, Nakamura S and Sugiura T (2001)
Early
Prediction of Final Infarct Size by Scintigraphic Estimation of Myocardial
Perfusion Immediately After Successful Primary Coronary Angioplasty.
XXII th
congress of the European Society of Cardiology, Stockholm Sweden.
- Mori Y, Uchiyama-Tanaka Y, Kosaki A, Matsubara H and Iwasaka T (2001)
Involvement of EGF/FRK transactivation pathway in TGF-¦Â-induced MCP-1
expression in renal tubular epithelial cells.
The 36th Annual meeting of American
society of nephrology, San Francisco.
- Uchiyama-Tanaka Y, Matsubara H, Masaki H, Shibasaki Y and Iwasaka T (2001)
TGF-¦Â signaling in glomerular mesangial cells: Involvement of HB-EGF and
EGF receptor transactivation in TGF-¦Â-induced fibronectin expression.
The 36th
Annual meeting of American society of nephrology, San Francisco.
- Yuyama R, Yuasa F, Mimura J, Kawamura A, Sugiura T and Iwasaka T(2001)
Endothelial-mediated vasoconstriction is not involved in the sympathetic
neural outflow in patients with heart failure.
XXIII congress of the european society of cardiology, Sweden.
- Kawamura A, Yuyama R, Yuasa F, Mimura J, Sugiura T and Iwasaka T(2001)
The effect of clonidine on baroreflex control of heart rate and sympathetic nerve
activity in patients with heart failure.
XXIII congress of the european society of cardiology, Sweden.
- Nishiue T, Kamihata H, Matsubara H, Fujiyama S, Tsutsumi Y, Tokioka M and
Iwasaka T(2001)
Myocardial Contrast Echocardiography is a Feasible Method
to Evaluate Neovascularization by Autologous Implantation of Bone Marrow
Cells.
50th American college of cardiology ,Orland.
- Kamihata H, Matsubara H,Nishiue T, Fujiyama S, Iba O, Tateishi E and
Iwasaka T (2001)
Evaluation of Potential Side-Effects by Implantation of Bone
Marrow-Derived Mononuclear Cells intoPorcine Ischemic Myocardium.
American Heart Association Scientific Session , Anahaim¡¡
- Okigaki M, Matsubara H and Iwasaka T (2001
) Critical Role of PYK2 in
Macrophage Function which are involved in Atherogenesis.
American Heart Association Scientific Session , Anahaim
- Tateishi E, Matsubara H, Murohara T, Shintani S, Imaizumi T and Iwasaka T(2001)
Efficacy and safety of therapeutic angiogenesis using autologous bone marrow
cell implantation for critical limb ischemia.
American Heart Association Scientific
Session , Anahaim
Ãø¡¡¡¡½ñ
- ¾¾¸¶¹°ÌÀ¡¢´äºäÔèÆó(2001)
¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥ó¶¼õÍÆÂÎÙɹ³Ìô¤Î¿´Êݸî¸ú²Ì¡©
(EBM½Û´Ä´ï¼À´µ¤Î¼£ÎÅ). Ãæ³°°å³Ø¼Ò 235-242
- ¾¾¸¶¹°ÌÀ, ´äºäÔèÆó (2001)
Kew word ¿´Â¡ÉÂ:¥¢¥ó¥¸¥ª¥Æ¥ó¥·¥ó¶¤È¤½¤Î
¼õÍÆÂÎ. Àèü°å³Ø¼Ò 38-41
- ÄÔ¡¡µ×»Ò (2001)
¡¡Æ°Ø©¤Ëȼ¤¦¿´ÅÅ¿Þ. Clinical Nursing Guide 23 ¿´ÅÅ¿Þ
¡Ê´äºäÔèÆóÊÔ¡Ë¡¡174¡Ý204ÊÇ. ¥á¥Ç¥£¥«½ÐÈÇ¡¢Âçºå
- ¿ÝëÊÝÉס¢ÌÌÚ¹¨ (1998)
µÞÀº¸¿´ÉÔÁ´. ¿´Â¡É¥ץ饯¥Æ¥¤¥¹19¡Ö¥¨¥Þ
¡¼¥¸¥§¥ó¥·¡¼¤ò¾è¤êÀÚ¤ë¡×¡ÊÊÌÉÜ¿µÂÀϺÊÔ¡Ë170-176ÊÇ.ʸ¸÷Ʋ¡¢Åìµþ
Ê¿À®13ǯ¶ÈÀÓÌÜÏ¿°ìÍ÷¤ËÌá¤ë